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ABSTRACT
Current research suggests resveratrol, a phytoalexin found predominately in grapes, may
function as a chemopreventive and/or chemotherapeutic agent for various cancers, including
colorectal cancer. However, the underlying mechanism(s) involved in these activities remain
elusive. Thus, the objective of the studies discussed here sought to investigate the effect of
resveratrol treatment on gene modulation in human colorectal cancer cells in order to identify
and characterize novel molecular targets that contribute to the observed anticancer activities of
resveratrol. Here, we identify activating transcription factor 3 (ATF3) and early growth
response-1 (Egr-1) as novel targets of resveratrol and provide data to elucidate the mechanism(s)
of regulation and how each target contributes to the anticancer effect of resveratrol in colorectal
cancer cells. We demonstrate the involvement of resveratrol in ATF3 transcriptional regulation,
which is facilitated by Egr-1 and Krüppel-like factor 4 interactions, and show that ATF3
contributes, at least partially, to resveratrol-induced apoptosis (Chapter 3). Moreover, we
suggest that increased Egr-1 transcriptional activity by resveratrol requires posttranslational
acetylation of Egr-1 in a SIRT1-independent manner. This acetylation by resveratrol may
contribute to Egr-1-mediated expression of the pro-apoptotic protein nonsteroidal antiinflammatory drug (NSAID)-activated gene-1 (NAG-1) induced by the phytoalexin (Chapter 4).
Taken together, the work presented here provide (1) novel mechanisms by which resveratrol
induces ATF3 and Egr-1 expression and (2) represent additional explanations for the antitumorigenic/anti-carcinogenic effects of resveratrol in human colorectal cancer cells.
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CHAPTER 1:
Molecular Targets of Resveratrol in Carcinogenesis
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This chapter is revised based on the Baek SJ and Whitlock NC book chapter published by
Springer Science+Business Media:
Baek SJ and Whitlock NC. Molecular targets of resveratrol in carcinogenesis. In:
Cho WCS, ed. Evidence-Based Anticancer Materia Medica. Dordrecht, Netherlands:
Springer Science+Business Media; 2011: 313-340.
My contributions to this work include: (1) gathering and reviewing the literature, (2) creating
tables and figures, (3) drafting and revising the chapter, and (4) final approval of the
published version. SJB revised and approved the final version for publication.

1.1. Abstract
Resveratrol, a dietary phytoalexin readily available in the diet, is reported to possess
anti-tumorigenic and anti-inflammatory activity in several cancers. However, the molecular
mechanisms and/or targets underlying the anti-tumorigenic activity of this compound remain
largely unknown. As a potential signaling pathway modulator, resveratrol is shown to affect
a multitude of signaling transduction pathways, and it is likely that this collective activity
may play an important role in resveratrol-induced anti-tumorigenesis. Therefore, the
elucidation of molecular targets of resveratrol is necessary to understand how this compound
is beneficial in anti-tumorigenic processes. Studies to identify molecular makers have
recently spawned increasing examination of possible targets of resveratrol as related to
anticancer proteins. These include, but are not limited to: (1) inhibition of carcinogenic
activation and induction of detoxification by phase I and phase II xenobiotic metabolizing
enzymes, respectively, (2) modulation of cell survival and apoptosis, (3) suppression of proinflammatory signaling pathways, and (4) inhibition of angiogenesis, invasion, and
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metastasis. This chapter summarizes the diverse molecular targets of resveratrol in the
prevention and treatment of carcinogenesis.

1.2. Introduction
Although advances in chemoprevention and chemotherapy have been achieved,
cancer remains the second leading cause of death in the United States (1). As such, it has
become increasingly clear that the problem of cancer cannot be solved by traditional
treatment alone and an alternative approach is needed. Traditional approaches to cancer
prevention have included attempts to eliminate carcinogenic agents and to detect and remove
precancerous lesions; many of these efforts are focused on interrupting, reversing, or
delaying the neoplastic process and remain largely ineffective and cumbersome (2). Yet,
epidemiological and current laboratory studies suggest consumption of certain fruits and
vegetables, containing phytochemicals, is associated with reduced cancer risk (3). It is
postulated that these dietary phytochemicals can function as chemopreventive and/or
adjuvant chemotherapeutic agents (3). However, further molecular mechanism-based studies
are required to evaluate the use of dietary components in cancer chemoprevention and
chemotherapy.
One such phytochemical of particular interest is resveratrol (3, 4’, 5trihydroxystilbene), a naturally occurring phytoalexin readily available in the diet and to
which a plethora of health-promoting effects have been ascribed. Resveratrol, first identified
as a bioactive compound in 1992, is found in several plants, particularly in the skin of red
grapes (4). This compound has elicited much attention as a potential anticancer agent since its
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inhibitory effect on carcinogenic processes (initiation, promotion, and progression) was first
reported in 1997 (5). Subsequently, numerous studies using both in vitro and in vivo model
systems have illustrated resveratrol’s capacity to modulate a multitude of signaling pathways
associated with cellular growth and differentiation, apoptosis, angiogenesis, invasion, and
metastasis (6). Thus, resveratrol modulates multiple signaling pathways that interrupt the
carcinogenic process and is also capable of extending one or more stages of this process
(Figure 1.1).
Despite substantial progress in understanding the molecular basis of resveratrol’s
anticancer activities, few clinical trials have been undertaken to confirm its use as a
chemopreventive and/or adjuvant chemotherapeutic agent. Preclinical studies have
demonstrated the inhibitory effects of resveratrol in different cancers (Table 1.1) (7) and its
ability to act as an adjuvant to traditional chemotherapeutics (8-12). As an adjuvant,
resveratrol potentiates the cytotoxic effects of anticancer drugs given at sub-toxic levels as
well as alleviate chemotherapeutic drug-associated side effects.
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Figure 1.1. The chemopreventive and chemotherapeutic effects of resveratrol. From “Molecular
targets of resveratrol in carcinogenesis” in Evidence-based Anticancer Materia Medica © 2011
Springer Science + Business Media. All rights reserved. Used with the kind permission of Springer
Science + Business Media.

5

Table 1.1. Chemopreventive and chemotherapeutic effects of resveratrol: in vivo evidence.
Experimental Model
Breast cancer
SD rats (♀), DMBAinduced
Colon cancer
C57B/6 mice, AOM +
DSS-induced
Liver cancer
SD rats (♀), DENA +
phenobarbital-induced
Pancreatic cancer
Nude mice (♂), MIA
PaCa2 cells

Skin cancer
B6D2F1 mice (♀),
doxorubicin-resistant
B16 melanoma cells
SENCAR mice (♀),
DMBA-induced
SKH-1 hairless mice
(♀), UVB-induced

Swiss albino mice (♀),
DMBA-induced

Dose/Route

Effects

Mechanisms

References

10 ppm, 127 d; diet

↑latency period,
↓incidence/multiplicity

↓NF-κB activation,
↓COX2, ↓MMP-9

(93)

300 ppm, 70 d; diet

↓incidence/multiplicity,
↓tumor volume

↓COX2, ↓TNFα,
↓iNOS

(80)

50-300 mg/kg/d, 20
wk; diet

↓incidence/multiplicity

↓proliferation, ↑Bax,
↓Bcl2

(63)

40 mg/kg, 4 wk; p.o.

↓tumor formation,
↓volume/growth

↓proliferation,
↓microvessel density,
↓NF-κB, ↓cyclin D1,
↓COX2, ↓MMP9,
↓survivin

(12)

12.5 mg/kg, 30 d; s.c.

↓tumor growth,
↑survival of tumor
bearing mice
↓epidermal hyperplasia

1-10 µM, 2/wk for
4wk; topically
10 µM, 7 treatments
on alternate days;
topically

25-50 µM, 3/wk for
28 wk; topically

↓epidermal hyperplasia

↓incidence/multiplicity,
↓tumor volume

(11)

(25)
↓leukocyte infiltration,
↓proliferation,
↓cdk2/6/4, ↓cyclin
D1/D2, ↑p53/p21,
↓MAPK pathway
↑apoptosis: ↑p53,
↑Bax, ↑cytochrome c
release, ↑caspase
activation, ↓Bcl2,
↓survivin, ↓PI3K/Akt
pathway

(53)

(66)

From “Molecular targets of resveratrol in carcinogenesis” in Evidence-based Anticancer Materia
Medica © 2011 Springer Science + Business Media. All rights reserved. Used with the kind
permission of Springer Science + Business Media.
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A Phase I clinical study is underway to determine potential adverse resveratrol-drug
interaction(s) with emphasis on CYP3A4 activity; the CYP3A4 enzyme is involved in the
metabolism of transplant medications/chemotherapies and is inhibited by resveratrol (13).
Other clinical trials seek to determine the effects of resveratrol on Wnt signaling in normal
mucosa and colon cancers (www.clinicaltrials.gov). Although shown to be well tolerated in
humans, the bioavailability of resveratrol remains poor (14). Thus, in order to recommend use
of resveratrol as a chemopreventive or adjuvant chemotherapeutic, further studies are
necessary to enhance bioavailability of this phytochemical as well as to validate identified in
vitro/in vivo targets of resveratrol. To this end, studies have begun evaluating techniques to
enhance resveratrol systemic bioavailability based on combinations with compounds that
inhibit the in vivo metabolism, nanoparticle-mediated delivery, use of naturally or synthetic
derivatives, and/or use of conjugated metabolites of resveratrol (15). Yet, resveratrol remains
a promising candidate for the prevention and treatment of cancers. This chapter summarizes
identified molecular targets of resveratrol that contribute to its activities in the prevention and
treatment of carcinogenesis.

1.3. Regulation of Phase I and Phase II Xenobiotic Metabolizing Enzymes
Oxidative metabolism by phase I enzymes, such as those belonging to the cytochrome
P450 (CYP) family, results in the conversion of pro-carcinogens to reactive electrophilic
intermediates, which are further metabolized by phase II enzymes via the conjugation of
hydrophilic moieties. Resultant metabolites are detoxified and eliminated. However,
inadequate detoxification by phase II enzymes potentiates genotoxicity (e.g. DNA and
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protein adduct formation) of phase I products, thus initiating the carcinogenic process (16, 17).
Reports of modification of both phase I and phase II xenobiotic metabolizing enzymes by
resveratrol suggest an explanation for the compound’s chemopreventive effect (Figure 1.2).
Two primary molecular mechanisms have been identified: (1) inhibition of AhR-dependent
and AhR-independent activation of phase I enzymes and (2) induction of Nrf2-mediated
activation of phase II enzymes.

Figure 1.2. Effect of resveratrol on AhR/Nrf2 signaling pathways. See text for AhR and Nrf2
pathway description. (A) Resveratrol inhibits AhR/ARNT recruitment to XRE-driven promoters (red
line) and is suggested to displace PAH binding, thus stabilizing cytosolic AhR complex (dotted line);
see text for refs. (B) Resveratrol promotes Nrf2 nuclear translocation via Keap1 dissociation. This
results in dimerization with small Maf (sMaf) and activation of ARE-driven promoters (18).
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1.3.1. Aryl hydrocarbon receptor (AhR)
Resveratrol is reported to alter phase I enzyme expression and activity in both an
AhR-dependent and AhR-independent manner (19). The canonical AhR-dependent signaling
pathway is thought to contribute to carcinogenic initiation by phase I enzyme-activated
polycyclic/poly-halogenated aromatic hydrocarbons (PAH/PHAH), and inhibition of AhR
signaling by resveratrol is thought to suppress this initiative process. Under basal conditions,
unbound AhR forms a multimeric complex in the cytosol. However, upon ligand binding
(e.g. binding by PAH/PHAHs), AhR translocates to the nucleus (shedding the multimeric
complex), forms a heterodimer with the AhR nuclear translocator (ARNT), and binds to gene
promoters containing xenobiotic response elements (XREs) resulting in the transactivation of
phase I enzymes (20).
Several reports demonstrate the inhibitory effects of resveratrol on AhR-mediated
activation of phase I enzymes. For example, resveratrol was shown to impair TCDD (2, 3, 7,
8-tetrachlorodibenzo-p-dioxin)-induced recruitment of AhR and ARNT to the CYP1A1/1B1
and CYP1A1/1A2 promoter in MCF-7 breast and HepG2 liver cancer cells, respectively,
resulting in decreased expression (21). Resveratrol also effectively blocked TCDD-induced,
AhR-dependent transcription in both an estrogen receptor (ER)-dependent and ERindependent manner (22, 23). Using ER-positive cancer cells, Perdew et al. (22) observed that at
micromolar concentrations, resveratrol reduced the AhR/ARNT complex at the CYP1A1
promoter, resulting in near-complete inhibition of CYP1A1 expression and metabolic
activity; however, at nanomolar concentrations, resveratrol repressed AhR-mediated
induction of CYP1A1 without interfering with AhR association with XREs after TCDD
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exposure. On the other hand, MacPherson and Matthews (23) showed resveratrol’s
competitive displacement of TCDD from AhR, indicating prevention of TCDD-induced
CYP1A1/1B1 expression mediated by AhR/ARNT complex recruitment to the promoter in
both ER-positive and ER-negative breast cancer cells. Furthermore, resveratrol was
demonstrated to reverse TCDD-induced, AhR-mediated CYP1A1 and matrix
metalloproteinase (MMP) 9 expressions in the gastric cancer cell line AGS (24).
Moreover, resveratrol effects phase I enzymes in an AhR-independent manner; the
phytochemical is shown to directly inhibit the expression and activity of these enzymes.
Resveratrol effectively blocked CYP1A1 and/or CYP1B1 expression and activity induced by
B[a]P (benz[a]pyrene), DMBA (7, 12-dimethylbenz[a]pyrene), dioxin, or TCDD in
differentiating keratinocytes (25, 26), immortalized bronchial epithelial cells (27), and breast
cancer cells (19, 28, 29). Resveratrol also suppressed CYP1A1/1B1 expression in vivo utilizing
a Balb/c animal model (30, 31). Furthermore, Mikstacka et al.(32) suggest that the addition of
thiol- and methoxy-groups to the resveratrol backbone increased selectivity for and inhibition
of CYP1A1 and CYP1B1.
In addition to modulation of CYP1A1/CYP1B1 expression and activity, resveratrol is
demonstrated to negatively regulate other CYP family members: inhibition of B[a]P-induced
CYP1A2 and CYP2B expression (31) and abrogation CYP2E1 catalytic activity (33) in vivo.
CYP3A4, which is predominantly overexpressed in colon and liver cancers, has been found
to be inhibited by resveratrol (13). Thus, resveratrol plays a suppressive role in AhRdependent and AhR-independent (e.g. effecting CYPs directly) activation of phase I
enzymes, contributing to the anticancer activity of this dietary phytoalexin.
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1.3.2. Nuclear factor E2-related factor 2 (Nrf2)
Induction of Nrf2 signaling by resveratrol is thought to confer protection against
phase I enzyme-activated carcinogens and associated carcinogenicity via the transactivation
of antioxidant and phase II detoxifying enzymes (34). Under basal conditions, Kelch-like
ECH-associated protein 1 (Keap1) sequesters Nrf2 in the cytoplasm, targeting the
transcription factor for proteasomal degradation. However, when induced by electrophiles,
reactive oxygen species, or dietary phytochemicals, Nrf2 dissociates from Keap1 and
translocates to the nucleus where it dimerizes with small Maf proteins and activates
antioxidant response element (ARE)-driven promoters (18, 34).
Bishayee et al. (35) demonstrated that attenuation of DENA (diethyl nitrosamine)induced liver carcinogenesis by resveratrol was mediated by increased Nrf2 expression.
Resveratrol induction of NAD(P)H quinone oxidoreductase (NQO1) expression in TCDDtreated MCF10F immortalized breast cells involved Nrf2, leading to suppression of DNA
adduct formation (28). NQO1 was also increased by resveratrol after 4-hydroxyestradiol and
estradiol-3-4-quinone treatment (36). Induction of Nrf2 signaling by resveratrol resulted in
increased expression of NQO1, heme-oxygenase-1 (HO-1), and glutamate cysteine ligase
(GCL) catalytic subunit in cigarette smoke extract (CSE)-treated bronchial epithelial cells
(37)

. Kode et al. (38) observed restored glutathione levels in CSE-treated A549 lung alveolar

epithelial cancer cells by resveratrol; this effect was mediated via Nrf2-induced GCL
expression and activity through the inhibition of CSE-modified Nrf2 posttranslation.
Resveratrol protected primary hepatocytes exposed to oxidative stress via increased Nrf2mediated NQO1, catalase, superoxide dismutase, glutathione reductase, glutathione
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peroxidase, and glutathione-S-transferase expression (39). Furthermore, resveratrol increased
NQO1 expression and activity in K562 leukemia cell line, which was associated with
resveratrol-induced Nrf2/Keap1 complex disruption, Nrf2 nuclear translocation, and
subsequent binding to ARE within the NQO1 promoter (40). These results indicate that Nrf2
is a key protein that controls resveratrol-induced anti-tumorigenesis in several cancers. In
contrast, Kawai et al. (41) observed Nrf2 cytoplasmic accumulation and inhibition of Nrf2dependent transcription by resveratrol, presumably mediated through induced sirtuin 1
(SIRT1) deacetylase activity, in both K562 leukemic and HepG2 hepatocellular carcinoma
cell lines. Thus, resveratrol could affect not only translocation but also accumulation of
Nrf2, potentially contributing to these context-dependent observations.

1.4. Modulation of Cell Cycle Progression and Apoptosis
The deregulation of cell cycle machinery and evasion of apoptosis, which contribute
to aberrant cell proliferation and survival, are considered a fundamental hallmark of cancer
development (42, 43). Therefore, identification of agents that target this abnormal signaling
offers an important strategy for both chemoprevention and chemotherapy. Resveratrol is one
such compound; several studies have demonstrated that the anti-proliferative effect of
resveratrol on cancer cells is attributable to inhibition of multiple pro-survival signaling
pathways (44, 45).
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1.4.1. Cell cycle proteins
Eukaryotic cell replication involves a series of processes collectively known as the
cell cycle (46). The cell cycle is divided into two major events: (1) interphase (divided into
four phases: G0, G1, S, and G2), in which the cell grows and accumulates nutrients, and (2)
mitosis (M), where the cells divide into two daughter cells. Proper functioning of the cell
cycle is important; the presence of numerous internal checkpoints allows the cell to detect
genetic damage and stalls cell cycle progression until these aberrations are repaired or
apoptosis is triggered. Failure of DNA quality control by checkpoints (and loss of regulatory
balance) facilitates uncontrolled cell proliferation and the development of cancer (46).
Cyclins and cyclin-dependent kinases (CDKs) are key regulatory molecules
governing the ordered processes of the cell cycle. Activation of CDKs by cyclins results in
the phosphorylation of target proteins, leading to the activation or inactivation of these
targets, and facilitates progression into the next phase of the cell cycle. Of the many cyclins,
cyclin D1 is an important cell cycle regulator involved in the G1/S phase transition and in the
regulation of proliferation and differentiation. Cyclin D1, produced in response to growth
factors, is often increased in various cancers due to deregulated degradation (43).
Resveratrol is reported to induce G1/S or G2/M phase cell cycle arrest in many cancer
cell lines, attributable to the modulation of cyclin-associated CDK proteins (44). Experiments
in cell culture revealed that down-regulation of cyclin D1 and/or CDK4/6 by resveratrol
resulted in the inhibition of cell proliferation, growth arrest, and subsequent induction of
apoptosis. Such an effect was observed in studies of the bladder (47), breast (48), colon (49),
liver (50), multiple myeloma (8), pancreas (12), prostate (51, 52), and skin cancer cells (11, 53).
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These results were also observed in vivo utilizing an UVB-induced model of skin
tumorigenesis (54). Resveratrol treatment of colorectal cancer cells also inhibited expression
of cyclin D1 and its complex formation with CDK4 (55); it is likely that resveratrol-induced
cyclin D1 suppression may result from -catenin inactivation in colorectal cancer cells and
should be considered a molecular target in these cancers (49). Moreover, treatment with
resveratrol potentiated the cytotoxic effects of the chemotherapeutic drugs doxorubicin and
gemcitabine in chemo-resistant B16 melanoma and pancreatic cancer cells, respectively, in
vitro and inhibited tumor growth in vivo (11, 12).
The CDK inhibitor p21 interacts with cyclin-CDK complexes to negatively regulate
their expression and is responsible for the G1 phase arrest phenotype (43). In contrast to
cyclin D1, resveratrol-mediated cell cycle arrest is associated with p53-mediated p21
expression. Activation of p21 or p27 by resveratrol was observed in bladder (47), breast (48),
liver (56), lung (57), prostate (51), and skin cancer cells (53, 54). Cell cycle arrest was associated
with apoptosis. Interestingly, Castello and Tessitore (58) demonstrated resveratrol inhibition
of U937 leukemic monocyte lymphoma cell proliferation was associated with increased
cyclin A and cyclin E expression, concomitant p21 and ribonucleotide reductase inhibition,
and the absence of apoptosis.

1.4.2. Apoptosis
Apoptosis, or programmed cell death, involves a series of biochemical events that
lead to a variety of morphological changes such as blebbing, cell membrane asymmetry and
attachment, cell shrinkage, nuclear fragmentation, chromatin condensation, and chromosomal
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DNA fragmentation (59). Apoptosis removes damaged and unwanted cells and maintains
tissue integrity and function (59).
p53 tumor suppressor: The tumor suppressor protein p53 is a critical transcription
factor involved in the regulation of cell proliferation and apoptosis; as such, it is a key
mediator in the prevention of carcinogenesis (60). It has been shown that resveratrol can cause
apoptosis through p53-dependent and p53-independent pathways (44). Several groups,
including our laboratory, have implicated the activation of p53-dependent pathway(s) in the
observed anti-proliferative effects of resveratrol. For example, Heiss et al. (61) demonstrated
that chronic administration of resveratrol at a sub-apoptotic dose resulted in senescent-like
growth arrest in different carcinoma cell lines. This effect was due to increased reactive
oxygen species generation, ataxia telangiectasia mutated kinase (ATM) and p53 activation
(via p38MAPK-mediated p53 phosphorylation at serine 15), induction of p21, and
subsequent induction of senescence. Utilizing both in vitro and in vivo models of
tumorigenesis and carcinogenesis, resveratrol is also shown to induce apoptosis via activation
of both intrinsic (mitochondria-mediated) and extrinsic (death receptor-mediated) pathways
(44)

. Resveratrol altered the Bax:Bcl2 protein ratio in the A431 epidermoid cancer cell line,

leading to mitochondrial membrane depolarization and subsequent induction of caspasedependent apoptosis, presumably mediated through p53 activation (62). Similar results were
observed in breast (63) and in the DENA-initiated, phenobarbital-promoted in vivo model of
liver carcinogenesis (64). Resveratrol increased p53-mediated expression of pro-apoptotic
proteins (e.g. Bax, Bak, Bim, PUMA, Noxa, etc.) and the release of mitochondrial proteins
(e.g. cytochrome c, Smac/DIABLO, etc.) to the cytosol, thus triggering suppression of
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inhibitors of apoptosis proteins (Bcl2, Bcl-XL, survivin, XIAP, etc.) and caspase activation
in various cancer cell lines (9, 10, 65-67). In addition, resveratrol induced the redistribution of
death receptors to membrane lipid rafts in colorectal and multiple myeloma/T cell leukemia
cancer cells, thus sensitizing these cells to death receptor-mediated apoptosis (68, 69).
Furthermore, resveratrol sensitized TNF-related apoptosis-inducing ligand (TRAIL)dependent cell death in androgen-sensitive and androgen-insensitive prostate cancer cells (9,
10)

.
How resveratrol increases p53 expression is not clear; it is believed that resveratrol

treatment causes DNA damage, which facilitates p53 activation. Tyagi et al. (70) observed
resveratrol-induced cell cycle arrest was mediated through increased Cdc2 tyrosine 15
phosphorylation via the activation of the DNA damage pathway (i.e. ATM/ATR-Chk1/2Cdc25 pathway). Resveratrol treatment also suppressed the metastasis-associated protein1/nucleosome remodeling deacetylation complex, allowing for increased p53 acetylation and
subsequent activation of pro-apoptotic genes (71).
Forkhead box, subgroup O (FoxO) transcription factor: Proteins known as FoxO,
divergent members of the Fox/winged-helix transcription factor superfamily, are recognized
tumor suppressors that play a critical role in cell fate decisions (72). Composed of four
members (FoxO1, 3, 4, and 6), FoxO transcription factors coordinate the expression of genes
involved in diverse cellular processes, including cell cycle progression, apoptosis, and
oxidative stress response. The function of FoxO proteins is regulated by posttranslational
modification(s), specifically phosphorylation and acetylation, which dictates their subcellular
localization and transcriptional activity (73).
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Abrogation of FoxO function occurs in numerous cancers due in large part to the
constitutive activation of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, a key
regulator of FoxO activity. PI3K/Akt-mediated phosphorylation results in the inactivation of
FoxO transcription factors. FoxO phosphorylation by PI3K/Akt facilitates their interactions
with 14-3-3 chaperone proteins and nuclear export; cytoplasmic sequestration inhibits FoxOdependent transcription (72). FoxOs are also regulated by de/acetylation in response to
oxidative stress. Several studies identify FoxOs as targets of the NAD-dependent class III
histone/protein deacetylase SIRT1. Under conditions of oxidative stress, SIRT1 forms a
complex with and deacetylates FoxO transcription factors, resulting in the preferential
activation of cell cycle arrest/stress resistance-related genes, thereby promoting cell survival
(74-76)

. Furthermore, silencing of SIRT1 resulted in FoxO4-mediated apoptosis in epithelial-

derived cancer cells (77). Thus, targeting these inhibitory pathways may prove advantageous
in the prevention/treatment of cancers.
The activation of FoxO transcription factors is implicated in the observed anticancer
activities of resveratrol. Using prostate cancer cells, Chen et al. (78) demonstrated
resveratrol’s ability to inhibit the phosphorylation of PI3K/Akt (i.e. PI3K/Akt inactivation)
resulted in decreased FoxO phosphorylation. Resveratrol increased nuclear translocation,
DNA binding affinity, and transcriptional activity of FoxOs. Furthermore, the antiproliferative/pro-apoptotic effect (Bim/TRAIL/DR4/DR5/p27Kip induction and cyclin D1
inhibition) of resveratrol on prostate cancer cells is FoxO-dependent. Similar results were
also observed in vivo (79). A schematic representation of resveratrol-mediated FoxO
regulation is shown in Figure 1.3.
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As described, SIRT1 induced FoxO deacetylation results in the preferential activation
of cell survival-related genes. Being that resveratrol is considered a SIRT1 agonist, although
currently controversial, one could speculate that the activation of a FoxO-mediated prosurvival mechanism may be induced by resveratrol-increased SIRT1 deacetylase activity.
Indeed, this is demonstrated in cardiomyocytes; resveratrol, presumably through SIRT1,
increased FoxO transcriptional activation of stress resistance-related genes and subsequent
phosphorylation by Akt (80). However, currently, the resveratrol/SIRT1/FoxO signaling axis
has not been studied in cancer cells thus allowing one to infer such an effect is context
dependent.

Figure 1.3. Effects of resveratrol on the FoxO signaling pathway. See text for FoxO pathway
description. Resveratrol is demonstrated to inhibit Akt activation and subsequent FoxO
phosphorylation and nuclear export. In contrast, resveratrol-induced FoxO expression facilitates
transactivation of forkhead response element (FHRE)-driven promoters (see text for refs.)GF, growth
factor; RTK; receptor tyrosine kinase.
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1.5. Suppression of the Inflammatory Signaling Pathway
Chronic inflammation contributes to the development of many diseases, including
cancer (81). For example, chronic colitis is associated with an increased risk of developing
colorectal cancer, and the susceptibility to cancer increases when the tissue is chronically
inflamed (82). Many tumors contain non-cancer cells, including immune and vascular cells
that are important in inflammation. The critical molecular interactions between neoplastic
cells and inflammatory cells remain unknown, but both pro- and anti-inflammatory mediators
are likely involved (81). Thus, it is clear the link between inflammation and cancer is strong
and that the interplay between the immune system and the development and remission of
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cancer is critical. These inflammatory processes contribute to the development and
progression of carcinogenesis, including tumor growth, angiogenesis, invasion, and
metastasis (81).

1.5.1. Nuclear factor- B (NF- B)
A key mediator of inflammation-induced cellular transformation is the transcription
factor NF- B. Cytoplasmic sequestration by I B prevents NF- B-dependent
transactivation. Upon activation, IKK phosphorylates I B resulting in its degradation, and
facilitates NF- B nuclear translocation and subsequent activation of transcription (83).
It has been postulated that the anticancer effects of resveratrol are attributable to the
inactivation of NF- B-dependent signaling. Resveratrol inhibited IKK -mediated I B
phosphorylation, resulting in increased I B expression, NF- B cytoplasmic retention, and
subsequent NF- B inactivation (84, 85). Resveratrol also blocked interleukin-1 (IL-1 )-,
tumor necrosis factor

(TNF )-, and HO-1-induced NF- B activation (86-88). Resveratrol

treatment of multiple myeloma cells resulted in cell cycle arrest and suppression of NF- Bdependent signaling related to proliferation (cyclin D1), survival (Bcl-2, Bcl-XL, XIAP, cIAP, and survivin), angiogenesis (vascular endothelial growth factor, VEGF), and metastasis
(MMP9 and IL-6) (8, 89). Similar results were observed in vivo using a DENA-initiated liver
carcinogenesis model (90) and Mia PaCa-2 orthotopic model of pancreatic cancer (12).
Furthermore, resveratrol prevented PMA (phorbol 12-myristate 12-acetate)-induced HT1080
fibrosarcoma cell adhesion to endothelial cells via modulation of intercellular adhesion
molecule-1 expression and NF- B activity (91). Taken together, it is clear that resveratrol not
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only curbs expression of NF- B, but also impedes the phosphorylation of I B thereby
keeping the constitutive NF- B subunit in an inactive state, resulting in suppression of the
inflammatory and pro-tumorigenic changes associated with this pathway (Figure 1.4).

1.5.2. Cyclooxygenase-2 (COX-2)
Overexpression of COX-2 is suggested to contribute to tumor development via
modulation of the multiple stages of tumorigenesis: cell survival signaling pathways,
angiogenesis, invasion, and metastasis (92). Resveratrol inhibited the expression and activity
of COX-2 through direct interaction with the enzyme’s catalytic domain (93). Zykova et al.
(94)

demonstrated inhibition of COX-2 activity (prostaglandin E2 synthesis), inhibition of

colony formation, and suppression of anchorage-independent growth in HT29 colon cancer
cells by this compound; COX-2 inhibition was absolutely required for resveratrol-mediated
activity. Resveratrol also reduced COX-2 expression in DENA-initiated liver (90), DMBAinitiated mammary (95), and TPA (12-o-tetradeconoylphorbol-13-acetate)-initiated skin (96)
carcinogenesis. Furthermore, using a DSS (dextran sodium sulfate)-induced mouse model of
colitis, resveratrol treatment was shown to reduce COX-2 expression (97, 98); similar results
were observed in DSS-induced, azoxymethane-promoted model of colitis-driven colon
cancer (82).

1.5.3. Pro-inflammatory cytokines: Tumor necrosis factor

(TNF ) and interleukins (ILs)

Pro-inflammatory cytokines, such as TNF and ILs, are important mediators of both
inflammation-related cancer and cancer-related inflammation. Expression of these cytokines
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is associated with carcinogenesis mediated via the activation of the NF- B signaling pathway
(81, 99)

. Resveratrol reversed colitis-associated expression of TNF , IL-6, and IL-1 induced

by DSS (82, 97, 98). Resveratrol suppressed IL-1 -stimulated cell proliferation, reduced IL-1 production, and IL-1 -induced NF- B activation in acute myeloid leukemia cells (86). Using
streptozotocin-nicotinamide-induced diabetic rats, Palsamy and Subramanian (100) reported
that resveratrol ameliorates induction of pro-inflammatory cytokines (e.g. TNF , IL-1 , IL6) in pancreatic -cells. Leiro et al. (101) proposed the anti-inflammatory activity ascribed to
resveratrol is related, in part, to the inhibition of TNF and IL-1 mRNA processing, which
resulted in reduced migration of head and kidney leukocytes in response to inflammatory
stimuli.

Figure 1.4. Effects of resveratrol on the NF- B signaling pathway. See text for NF- B pathway
description. Resveratrol is demonstrated it inhibit NF- B signaling at all steps (see text for refs).
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1.6. Inhibition of Angiogenesis, Invasion, and Metastasis
Angiogenesis, the formation of new blood vessels, is critical to tumor development
and growth, invasion, and metastasis (102). Neovascularization facilitates cell dissociation
from the primary tumor site, entry into circulation, and establishment of the tumor(s) at a
secondary site (a process termed metastasis) (103-105). Disruption of the angiogenic and
metastatic signaling cascades is another mechanism by which resveratrol exerts its
chemotherapeutic effect.
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1.6.1. Hypoxia inducible factor-1 (HIF-1 ) and vascular endothelial growth factor (VEGF)
Adaptation to hypoxia by tumor cells is mediated by HIF-1 , which regulates the
expression of proteins, such as VEGF, associated with angiogenic and invasive signaling
cascades (106). Treatment with resveratrol reduced expression of HIF-1 and VEGF in
ovarian cancer cells; resveratrol-mediated activity was attributed to inactivation of PI3K/Akt
and protein translational regulators, enhancement of HIF-1 proteasomal degradation, and
subsequent suppression of VEGF (107). These results were also observed in tongue squamous
cell carcinoma (108) and lysophosphatidic acid-stimulated ovarian cancer cells (109). VEGF
expression was also reduced in multiple myeloma (89) and endometrial cancer cells (110).
Additionally, the anti-migratory/angiogenic effects of resveratrol observed in human
umbilical vein epithelial cells was FoxO-dependent and predicated on PI3K/Akt pathway
inhibition; this observation was associated with decreased VEGF expression (111).

1.6.2. Matrix metalloproteinase 2 and 9 (MMP2 and MMP9)
Cell invasion and metastasis are facilitated via the proteolytic degradation of
basement membrane and connective tissue; this degradation of extracellular matrices creates
a channel by which tumors escape into circulation. MMPs are essential factors in this
process (81, 103). Numerous reports illustrate the anti-invasive and anti-metastatic properties of
resveratrol. Treatment with resveratrol inhibited heregulin- 1-mediated MMP9 expression
in breast cancer cells through the inactivation of ERK1/2 signaling resulting in suppression
of invasion (112). TNF -mediated MMP9 expression and invasion was also reduced in
resveratrol-treated hepatocellular carcinoma cells; this suppression was associated with
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down-regulation of NF- B signaling (87). Inactivation of NF- B signaling in lung
adenocarcinoma cells also contributed to the anti-invasive effect of resveratrol and led to
inhibition of HO-1-induced MMP9 expression, migration, and invasion (88). Resveratrol
blocked insulin growth factor-1 (IGF-1)-mediated cell migration in vitro through inactivation
of the PI3K/Akt signaling pathway and down-regulation of MMP2 induced by IGF-1 (113).
Moreover, resveratrol blunted TNF -induced monocyte adhesion and migration through
modulation of adhesion molecules and MMP2 enzymatic activity (114).

1.7. Other Molecular Targets
1.7.1. Topoisomerase II
Topoisomerases are ubiquitously expressed enzymes that regulate the topological
state of DNA; these enzymes remove knots and tangles from the genome through the
winding and unwinding of DNA, generating transient double-stranded breaks in the DNA
double helix to control cell division and proliferation. In malignant tumor cells, this enzyme
is overexpressed when compared to normal, quiescent cells; thus, topoisomerase II has been
suggested as a potential chemopreventive target (115). Resveratrol is demonstrated to inhibit
topoisomerase activity. Treatment of glioblastoma cells with the compound interfered with
decatenation (i.e. unwinding of DNA) by topoisomerase; these authors suggest resveratrol
acted as a “topoisomerase poison” due to the prolongation of the topoisomerase-DNA
complex (116).
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1.7.2. Human telomerase reverse transcriptase (hTERT)
Addition of hexametric repetitive sequences (referred to as telomeres) to
chromosomal ends by telomerase ensures and maintains genomic stability. With each cell
division, telomeres progressively shorten until a critical length is reached and the cell
undergoes senescence or apoptosis. In most cancers, telomerase is highly activated resulting
in tumor cell immortalization due to the maintenance of telomeres. This immortalization is
associated with increased expression of the telomerase catalytic subunit, hTERT (117).
Therefore, targeting telomerase and its catalytic subunit hTERT provides an additional
mechanism by which anticancer agents exert chemopreventive/chemotherapeutic effects.
Resveratrol has been shown to suppress telomerase activity in breast (118) and colon (119)
cancer cells associated with decreased nuclear levels of hTERT. Furthermore, resveratrol
treatment of osteosarcoma and lung cancer cells induced telomeric instability,
phosphorylation of histone H2AX and p53, and activation of DNA damage signaling (120).

1.8. Identification of Novel Molecular Targets
To identify novel molecular targets that mediate the anti-cancer activities of
resveratrol, our laboratory performed microarray analysis using HCT-116 human colorectal
cancer cells treated with resveratrol (50 µM) for 24 h (Table 1.2). Among the 519 genes
altered by resveratrol, three genes, ATF3, NAG-1, and DDIT3 were of particular interest due
to their suggested involvement as negative regulators of tumorigenesis and carcinogenesis.
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Table 1.2. Alteration of gene expression profiles of HCT-116 colorectal cancer cells by
resveratrol (50 μM). Select up- and down-regulated genes from microarray analysis.
Gene Symbol
Gene Name
GenBank No.
Up/Down
DDIT3
DNA-damage-inducible transcript 3
NM_004083
Up
ATF3
Activating transcription factor 3
NM_004024
Up
COBRA1
Cofactor of BRCA1
NM_015456
Up
OR8B8
Olfactory receptor, family 8, subfamily B, member 8
NM_012378
Up
AADACL1
Arylacetamide deacetylase-like 1
NM_020792
Up
PLK3
Polo-like kinase 3 (Drosophila)
NM_004073
Up
PCK2
Phophoenolpyruvate carboxykinase 2 (mitochondrial)
NM_004563
Up
NAG-1
NSAID-activated gene-1
NM_004864
Up
WNT16
Wingless-type MMTV integration site family, member 16 NM_016087
Down
C4orf18
Chromosome 4 open reading frame 18
NM_016613
Down
FANCC
Fanconi anemia, complementation group C
NM_000136
Down
PDE4B
Phosphodiesterase 4B
NM_001037
Down
IGFBP7
Insulin-like growth factor binding protein 7
NM_001553
Down
From “Molecular targets of resveratrol in carcinogenesis” in Evidence-based Anticancer Materia
Medica © 2011 Springer Science + Business Media. All rights reserved. Used with the kind
permission of Springer Science + Business Media.

1.8.1. Activating transcription factor 3 (ATF3)
ATF3 is a member of the ATF/cAMP response element binding protein (CREB)
family of bZIP transcription factors and is characterized as a stress inducible/adaptive
response gene (121). Much controversy exists as to the role of ATF3 in tumorigenesis due in
part to the observation of both positive and negative effects. Recently, a dichotomous role
was reported for ATF3 in cancer development; the authors concluded its role as a tumor
suppressor or oncogene is dependent on cell context and the extent of malignancy (122).
However, several lines of evidence suggest that ATF3 may function as a tumor suppressor,
which will be discussed further in Chapter 3 in addition to our recent findings.
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1.8.2. Nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1)
NAG-1, a divergent member of the transforming growth factor β superfamily of
cytokines, is suggested to play a role in a number of cellular processes, including
inflammation and cell survival. NAG-1 was first identified by Baek et al. (123) through PCRbased subtractive hybridization from an NSAID-induced library in human colorectal cancer
cells. NAG-1 was shown to be highly expressed in mature intestinal epithelial cells and
significantly reduced in human colorectal carcinomas and neoplastic intestinal polyps of Min
mice (124). NAG-1 overexpression reduced cell viability of breast cancer cells by up to 80%
(125)

and treatment of prostate cancer cells with purified NAG-1 induced apoptosis (126). In

addition, NAG-1 transgenic mice are resistant to the development of intestinal tumors
following treatment with azoxymethane or by introduction of a mutant APC gene (127).
Furthermore, subsequent studies have identified NAG-1 induction by a number of dietary
and naturally occurring compounds demonstrated to possess anticancer activity. These
include genistein (128), epicatechin gallate (129), indole-3-carbinol (130), conjugated linoleic acid
(131)

, berberine (132, 133), 6-gingerol (134), platycodon D (135), capsaicin (136), Astragalus

saponins (137), and the isoflavonoid formononetin (138). Increased NAG-1expression
contributed to the inhibition of cell proliferation and induction of apoptosis by these
compounds. Additionally, we and others have shown NAG-1 up-regulation by resveratrol
resulted in increased p53-mediated cell death in colorectal, lung, and osteosarcoma cancer
cells (139) and inhibition of cell proliferation in pancreatic cancer cells (140).
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1.8.3. DNA-damage-inducible transcript 3 (DDIT3)
DDIT3 is a critical mediator in the induction of cell cycle arrest and/or apoptosis in
response to ER stress. Transcriptional activation by ER stress results in downstream
regulation of genes involved in the modulation of cell survival. For example, DDIT3
expression inhibits Bcl2 and leads to Bax translocation to the mitochondria resulting in
activation of the intrinsic pathway of apoptosis (141). In several studies, resveratrol is
demonstrated to increase DDIT3 expression in colon (142, 143) and leukemia (144) cancer cells.
Increased DDIT3 expression contributed to induction of cell cycle arrest and/or induction of
apoptosis by resveratrol.

1.8.4. Other potential targets
Although gene alteration by resveratrol has yet to be validated, each of the
aforementioned genes (refer to Table 1.2) is suggested to act as either a negative or positive
regulator of tumorigenesis. COBRA1, an integral component of negative elongation factor
complex, is demonstrated to inhibit estrogen-dependent transcription and growth of breast
cancer cells in vitro. Furthermore, loss of COBRA1 is associated with breast cancer
progression and metastasis (145). Plk3, whose expression is rapidly increased in response to
DNA damage and cellular stress, is believed to behave as a tumor suppressor gene and serve
as a “functional link” in p53-induced cell cycle arrest and apoptosis (146). Thus, induction of
COBRA1 or Plk3 may play a role in resveratrol-mediated inhibition of proliferation or
induction of apoptosis in colorectal and other cancers. On the other hand, down-regulation of
WNT16, FANCC, or PDE4B by resveratrol may lead to enhanced inhibition of cell growth
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or sensitization to chemotherapy. For example, overexpression of WNT16 is associated with
oncogene-induced senescence via regulation of p53 activity (147) and enhanced cell
proliferation and clonogenicity of basal cell carcinomas (148). Disruption of FANCC, which
results in deactivation of the Fanconi anemia pathway, sensitizes cancer cells to DNA
damage and growth inhibition induced by DNA interstrand-cross-linking agents thereby
abrogating chemo-resistance (149-151). Moreover, increased PDE4B expression is associated
with inactivation of cAMP and abrogation of growth inhibitory effects of cAMP (152, 153).

1.9. Summary
As discussed in previous sections, resveratrol is demonstrated to modulate the
expression and/or activity of proteins involved in critical pathways of carcinogenesis. These
include carcinogen activation and detoxification, inflammation, angiogenesis, invasion and
metastasis. Although numerous molecular targets have been identified, the underlying
mechanisms involved in the antitumor/anticancer activities of resveratrol are not completely
understood. Thus, the objective of the studies discussed herein sought to investigate the
effect of resveratrol treatment on gene modulation in human colorectal cancer cells in order
to identify and characterize a novel molecular target(s) that may mediate the anticancer
activities of resveratrol.
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CHAPTER 2:
Materials and Experimental Methods
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2.1. Cell Lines and Reagents
All human cancer cell lines were purchased from American Type Culture Collection
(Manassas, VA) unless otherwise stated; authentication occurred via short tandem repeat
profiling, monitoring of cell morphology, and karyotyping. SqCC/Y1 head and neck
squamous cell carcinoma cell line was generously provided by Dr. Dong M. Shin (Emory
University, Atlanta, GA) and characterized previously (154). HCT-116 and HT-29 colorectal
carcinoma cells were maintained in McCoy’s 5A culture medium; SW480 colorectal
carcinoma cells were maintained in RPMI-1640 culture medium. Caco-2 colorectal
carcinoma cells and SqCC/Y1 were grown in DMEM culture medium. A549 lung epithelial
carcinoma cells, LoVo colorectal carcinoma cells, and PC3 prostate adenocarcinoma cells
were cultured in Ham’s F12 medium. All media were supplemented with 10% fetal bovine
serum, penicillin (100 U/mL), and streptomycin (100 μg/mL). Resveratrol was purchased
from Alexis Biochemicals (San Diego, CA), 3’3-diindolymethane (DIM) from Sigma
Aldrich (St. Louis, MO), and trichostatin A (TSA) and cycloheximide (CHX) from Fisher
Scientific (Pittsburgh, PA). All chemicals were dissolved in either dimethylsulfoxide
(DMSO) or ethanol. ATF3 (sc-188), Egr-1 (sc-110), KLF4 (GKLF4; sc-20691), and -actin
(sc-47778 HRP) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Acetylated Lysine (#9441), phosphor-SIRT1 (Ser27; #2327), and phosphor-SIRT1
(Ser47; #2314) antibodies were purchased from Cell Signaling Technology (Danvers, MA).
Anti-SIRT1 (clone 10E4; #04-1557) antibody was purchased from Millipore (Billerica, MA).
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2.2. Construction of Plasmids
For deletion analysis of the ATF3 promoter, pATF3 -1850/+34 (155) was serially
deleted using the Erase-a-Base System (Promega, Madison, WI) according to manufacturer’s
protocol. The pATF3 -514 del Egr-1 reporter construct was previously described (156).
Putative binding sites of KLF4 within the -514 bp region of the ATF3 promoter were deleted
using Stratagene’s QuikChange II Site Directed Mutagenesis Kit (La Jolla, CA) with KLF4A and KLF4-B deletion primers (see Table 2.1). pATF3 -514 del Egr-1 KLF4 reporter
construct was generated using pATF3 -514 del Egr-1 and KLF4-A deletion primers as
described. Deletions were confirmed by DNA sequencing. The ATF3 (pCG-ATF3) and
SIRT1 (pBABE/T1) expression vectors were kindly provided by Drs. Tsonwin Hai (Ohio
State University, Columbus, OH) and Thomas E. Eling (NIEHS, Research Triangle Park,
NC), respectively. KLF4 (pcDNA3.1/His/V5/KLF4) expression vector was generated using
human KLF4 specific primers (see Table 2.1). Egr-1 wild type (pcDNA3.1/NEO/Egr-1;
WT) expression vector was described previously (157); Egr-1 del AD, del ZD2, and
KDKK aDaa mutation constructs were generated using specific primers (see Table 2.1).
Sp1 (pCMV-Sp1) and p53 (pcDNA3.1/myc/His/p53) expression vectors were previously
described (139, 158). The pNAG-133/+41 and pEBS14luc reporter constructs were described by
Baek et al. (157, 158).

2.3. Microarray Analysis
HCT-116 colorectal cancer cells were treated with DMSO or resveratrol (50 or 100
μM) for 24 h. Total RNA was amplified using Agilent Low RNA Input Fluorescent Linear
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Amplification Kit (Santa Clara, CA) protocol. Starting with 500 ng of total RNA, Cy3- or
Cy5-labeled cRNAs was produced according to the manufacturer’s protocol. For each twocolor comparison, 750 ng of each Cy3- and Cy5-labeled cRNAs was mixed and fragmented
using Agilent in situ Hybridization Kit protocol. Hybridizations were performed for 16 h in a
rotating hybridization oven using Agilent 60-mer oligo microarray processing protocol. Data
was obtained using Agilent Feature Extraction Software (v7.5) using defaults for all
parameters. Intensity plots were rated for each ratio experiment, and genes were considered
“signature genes” if the p value was less than 0.001. Functional annotation of genes was
performed according to the Gene Ontology Consortium
(http://www.geneontology.org/index/shtml) by Gene Spring (v7.3).

2.4. Reverse Transcription and Quantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR and qRT-PCR)
Total RNA was isolated from HCT-116 cells treated with DMSO or resveratrol (50
μM) using 5 Prime Perfect RNA Cell/Tissue Kit (Gaithersburg, MD) and 1 μg of RNA was
reverse transcribed using Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Rockford,
IL). One μL of synthesized DNA was added to 24 μL of PCR reaction mixture containing
human specific gene primers (see Table 2.2). Thermo cycling occurred as follows: initial
denaturation at 94 C for 3 min followed by 30 (ATF3, DKK1, Egr-1, HO-1, KLF4, NAG-1,
Nur77 and PDE4B) and 25 (GAPDH) cycles at 94 C for 1 min, 55 C for 1 min, 72 C for 1
min, and final extension at 72 C for 10 min. PCR products were electrophoresed on 1.4%
agarose gel and photographed under ultraviolet light. The intensity of each band was

34

quantified using Scion Image software (Scion Corp., Frederick, MD) and normalized to
GAPDH, an internal control. Quantitative reverse transcription PCR (qRT-PCR) was
performed according to Fast SYBR Green Master Mix protocol (Applied Biosystems,
Carlsbad, CA) and analyzed using MyIQ Single Color Real-time PCR Detection System
(Bio-Rad Laboratories, Hercules, CA).

Table 2.1. Primers used for the construction of plasmids.
Construct
del KLF4-A
del KLF4-B
pM/Egr-1
del AD
del ZD2
KDKK aDaa
(Egr-1 aDaa)
KLF4 and
pVP16/KLF4

Forward Primer (5’ to 3’)
ccccctctctttcggccccgccttggcccc
ggcccctcctccttcctccgctcggttcgg
ttgaattcgccgcggccaaggccgag
catcacctatggcctagtgagcatgaccaaccc
ac
gccctcccagttcgcctgcgacatctgtggaag
aa
cggcaggcggacgcggcagcagacaaaagt
gttgtggcctcttcg
cgaattctatggctgtcagcgacgcg

Reverse Primer (5’ to 3’)
cggggccgaaagagagggggcactggtgatg
cggaggaaggaggaggggccaaggcggggc
ttaagcttgcaaatttcaattgtcc
tcactaggccataggtgatggggggcagtcgagt
g
cgcaggcgaactggaagggcttctggcctgtgtg
g
gtctgctgccgcgtccgcctgccgcaagtggatct
tggtatgcc
cccaagcttttaaaaatgcctcttcatgtgtaaggc

T able 2.2. Primers used for RT-PCR and/or qRT-PCR.
Gene
ATF3
DKK-1
Egr-1
HO-1
KLF4
NAG-1
Nur77
PDE4B
GAPDH

Forward Primer (5’ to 3’)
gtttgaggattttgctaacctgac
catcagactgtgcctcagga
ctgcgacatctgtggaagaa
atgacaccaaggaccagagc
cgaattctatggctgtcagcgacgcg
acgctacgaggacctgctaa
cacagcttgcttgtcgatgt
ataccgatcgcattcaggtc
tcaacggatttggtcgtatt

Reverse Primer (5’ to 3’)
agctgcaatcttatttctttctcgt
ggcaagacagaccttctcca
tgtcctgggagaaaaggttg
gtgtaaggacccatcggaga
cccaagcttttaaaaatgcctcttcatgtgtaaggc
agattctgccagcagttggt
tcttgtcaatgatgggtgga
agtggtggtgagggactttg
ctgtggtcatgagtccttcc
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2.5. RNA Stability
HCT-116 cells were grown to 60% to 80% confluence and pretreated with DMSO or
resveratrol (50 μM) for 24 h in serum-free media. After pretreatment, actinomycin D was
added directly to the media at a dose of 5 M to terminate transcription as indicated. Total
RNA was isolated and reverse transcribed. Reverse transcription PCR (RT-PCR) for ATF3
and GAPDH occurred as previously described.

2.6. Western Blot Analysis
Cells were grown to 60% to 80% confluence in 60 mm plates. For transient
transfections, plasmid mixtures containing 2.5 μg of Egr-1 WT or aDaa expression vector
were transfected for 5 h in serum-free media as described. Cells were serum starved
overnight and treated with resveratrol and/or trichostatin A (TSA) as indicated in serum-free
media. Protein lysates were isolated in ice-cold RIPA buffer (PBS, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS) supplemented with protease (1 mM PMSF, 1 μg/mL aprotinin, and
1 μg/mL leupeptin) and phosphatase (0.1 nM Na3VO4 and 25 mM NaF) inhibitors. Protein
concentrations were measured using BCA protein assay (Thermo Fisher Scientific) with
bovine serum albumin as the standard. Total protein was subjected to Western blot analysis
as described (156). Briefly, proteins (30 μg or 50 μg) were separated by SDS-PAGE (8-12%)
and transferred to nitrocellulose membrane (Pall Life Sciences, Pensacola, FL). Membranes
were blocked in 5% skim milk in TBS/0.05% Tween-20 (TBS-T) for 1 h and incubated with
specified antibodies at 4 C overnight. After three washes with TBS-T, blots were incubated
with horseradish peroxidase-conjugated secondary antibody for 1 h and washed three times.
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Protein signal was detected using Enhanced ChemiLuminescence System (Thermo Fisher
Scientific).

2.7. de novo Protein Synthesis
HCT-116 cells were grown to 60% to 80% confluence in 60 mm plates and pretreated
with CHX (10 mg/mL) for 30 min in serum-free media. After pretreatment, DMSO or
resveratrol (50 μM) was added directly to the media and incubated for 24 h. Total RNA was
isolated and reverse transcribed. Quantitative RT-PCR for ATF3 and GAPDH occurred as
described.

2.8. Transfection using Luciferase Reporter System
Transient transfections were performed using LipofectAMINE (Invitrogen, Carlsbad,
CA) according to manufacturer’s protocol. HCT-116 cells were seeded in 12-well plates at a
concentration of 2.0 x 105 cells per well. The next day, plasmid mixtures containing ATF3
promoter (0.5 μg) and pRL-null vector (0.05 μg) were co-transfected for 5 h in serum-free
media. For co-transfection experiments, 0.25 μg of the ATF3 promoter and 0.25 μg of
expression vector were co-transfected with 0.05 μg pRL-null vector. For competition assays,
plasmid mixtures were prepared as indicated in Figure A.9. To measure Egr-1 and NAG-1
activity, plasmid mixtures containing pEBS14luc (0.375 μg) and Egr-1 or SIRT1 expression
vector (0.375 μg or 0.25 μg) were co-transfected with 0.0075 μg pRL-null vector, as
indicated in Figures B.1 and B.4, using PolyJet DNA in vitro Transfection Reagent
(SignaGen Laboratories, Rockville, MD). After transfection, cells were treated with
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resveratrol (50 μM) in serum-free media for 24 h. Cells were harvested in 1X passive lysis
buffer, and luciferase activity was measured and normalized to pRL-null luciferase activity
using DualGlo Luciferase Assay Kit (Promega).

2.9. RNA Interference
Egr-1 sense and antisense oligonucleotides were previously described (156). ATF3 and
KLF4 siRNA were purchased from Santa Cruz Biotechnology; control siRNA was purchased
from Ambion (Austin, TX). HCT-116 cells were transfected with either 100 nM (ATF3 and
KLF4) or 200 nM (Egr-1) of each construct using TransIT-TKO transfection reagent (Mirus,
Madison, WI). After transfection for 24 h, cells were serum starved overnight and treated as
indicated in Figure A.5. Total protein was subjected to Western blot analysis as described.

2.10. Electrophoretic Mobility Shift Assay (EMSA)
HCT-116 cells were grown to 80% confluence. After overnight serum starvation,
cells were treated with resveratrol (50 μM) for 24 h. Cells were then washed with PBS and
nuclear extracts were prepared using Nuclear Extract Kit (Active Motif, Carlsbad, CA)
according to protocol. Double-stranded oligonucleotides corresponding to (F, 5’GTGAGCGAGGGCGGGG-3’) and KLF4 (F, 5’-TCCACCCCTTCCACCCCT-3’) binding
sites were synthesized and end-labeled with biotin (Operon, Huntsville, AL). Mutant
oligonucleotides of Egr-1 (F, 5’-GTGAGCGAAAACGGGG-3’) and KLF4 (F, 5’TCCAAAACTTCCAAAACT-3’) were also synthesized. To ensure specific binding of Egr1 and KLF4, recombinant proteins were generated using TNT Quick Coupled

38

Transcription/Translation System (Promega). EMSA was done using the LightShift
Chemiluminescent EMSA kit according to the manufacturer’s protocol (Thermo Fisher
Scientific). Briefly, biotin-labeled oligonucleotide (10 nM) was incubated with nuclear
extract (5 μg) or recombinant protein and 1X binding buffer (Promega) at room temperature
for 20 min. For competition assay, proteins were pre-incubated with unlabeled
oligonucleotide (10- or 100-fold) for 10 min.

2.11. Chromatin Immunoprecipitation
HCT-116 cells were grown to 80% confluence and treated with resveratrol (50 μM).
After 24 h, cells were fixed with 1% formaldehyde at 37 C for 10 min. The fixed cells were
scraped into conical tubes, pelleted, and lysed in lysis buffer containing protease and
phosphatase inhibitors. DNA was sheared into fragments by sonication 4 times at 10 s at
50% constant maximal power. The sonicated cell supernatant was diluted 10-fold in
immunoprecipitation buffer and 1% of diluted cell supernatant was kept as a control (input).
The chromatin was pre-cleared with protein A/G agarose, 20 μg heat-denatured salmon
sperm DNA, 50 μg bovine serum albumin, and 10 μg antibodies against Egr-1, KLF4, or IgG
overnight at 4 C. The immunocomplexes were washed five times with wash buffer and
eluted with elution buffer. Protein-DNA cross-links were reversed with 27 μL of 5 M NaCl
and 1 μL of 10 mg/mL RNAse A at 65 C for 4 h and incubated with 2 μL of 20 mg/mL
proteinase K at 45 C for 1 h. The DNA was purified by phenol extraction and ethanol
precipitation. The region between -298 and -114 bp of the human ATF3 promoter was
amplified by qRT-PCR and RT-PCR using F, 5’-CGGCTCCGGTCCTGATATGG-3’ and R,
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5’-AGAACCGGCCGAACGGAGCG-3’ as described. For NAG-1, the region between -133
and +41 bp of the promoter was amplified using F, 5’-CCAGAAATGTGCCCTAGCTT-3’
and R, 5’-GACCGGGACTGACCAGATG-3’. The 184 bp (ATF3) or 202 bp (NAG-1)
product was resolved on 2% agarose gel and visualized under ultraviolet light.

2.12. Mammalian 2-Hybrid Assay
The pM/Egr-1 and pVP16/KLF4 vectors for mammalian-2-hybrid were generated.
PCR fragments were amplified from pcDNA3.1/NEO/Egr-1 and pcDNA3.1/His/V5/KLF4
using Egr-1 and KLF4-specific primers, respectively (see Table 2.1). After PCR, fragments
were cloned into pCR2.1/TOPO vector (Invitrogen), digested with EcoRI and HindIII
restriction enzymes, and cloned into pM or pVP16 vectors. Deletion clones of pM/Egr-1
were generated as described using del AD and del ZD2 primers (Table 2.1). Mammalian-2hybrid assay was performed according to Matchmaker Mammalian Assay Kit 2 protocol
(Clontech, Mountain View, CA). Transfection with LipofectAMINE occurred as described
using plasmid mixtures containing 0.2 μg of pM/Egr-1 or deletion construct, 0.2 μg of
pVP16/KLF4, 0.2 μg of pG5Luc, and 0.06 μg pRL-null vector.

2.13. Immunoprecipitation
For immunoprecipitation of Egr-1 (WT and deletions, generated as described) and
KLF4, each expression vector was transfected into HCT-116 cells as indicated and grown to
confluence (see Figure A.11). For acetylation experiments, Egr-1 WT or aDaa mutation
expression vector was transfected into HCT-116 cells. Cells were then serum starved
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overnight and treated with resveratrol (50 μM) for 2 h. After washing with ice-cold PBS,
cells were harvested in RIPA buffer containing inhibitors and incubated on ice for 30 min.
Cell suspensions were centrifuged for 10 min, supernatant collected, and protein
concentrations were measured. Approximately 600 μg of protein and 5 μg of antibody (IgG,
Egr-1or KLF4) were incubated overnight at 4°C with shaking. The following day, lysateantibody mix was added to 50 μL protein A/G resin beads (Santa Cruz Biotechnology),
which was washed and re-suspended in RIPA buffer, and incubated overnight at 4°C with
shaking. After overnight incubation, samples were centrifuged for 30 s and the supernatant
removed. Protein A/G resin beads were washed 5 times with 500 μL ice-cold PBS, with
complete removal of PBS after each wash to prevent background. After the last wash, 60 μL
of 2X loading buffer was added to the resin beads, vortexed vigorously, and boiled at 100ºC
for 5 min to denature and separate the protein from the beads. Samples were then
centrifuged, supernatant collected, and Western blot analysis was performed using 10 μL of
sample as described.

2.14. Caspase 3/7 Enzymatic Activity
Apoptosis was measured using Apo-ONE Homogenous Caspase-Glo-3/7 Assay kit
(Promega) according to manufacturer’s protocol. Cells were harvested in RIPA buffer
containing protease and phosphatase inhibitors. The same volume of Caspase-Glo-3/7
reagent was added to cell lysates (30 μg protein) in 96-well plates and incubated at room
temperature in the dark for 1 h. Luminescence was measured using FLX800 microplate
reader (BioTek, Winooski, VT).
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2.15. Statistical Analyses
SAS for Windows (v9.2; SAS Institute, Inc., Cary, NC) statistical analysis software
was used. For multiple group comparisons, analysis of variance with Tukey’s multiple
comparison test was used to compare mean values. The Student’s t test was used to analyze
differences between samples. Results were considered statistically significant at *P <0.05,
**P <0.01, ***P <0.001.
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Chapter 3:
Role of Egr-1, KLF4, and ATF3 in Resveratrol-Mediated
Anticancer Activity
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This chapter is revised based on the article published by Whitlock et al.:
Whitlock NC, Bahn JH, Lee SH, Eling TE, and Baek SJ (2011). Resveratrol-induced
apoptosis is mediated by early growth response-1, Krüppel-like factor 4, and activating
transcription factor 3. Cancer Prevention Research 4(1): 116-127.
My contributions to this work include: (1) experimental design, (2) acquisition, analysis, and
interpretation of data, (3) gathering and reviewing the literature, (4) creating figures/tables,
and (5) drafting and revising the article. JBH generated the KLF4 and pVP16/KLF4
constructs. SHL performed ATF3 promoter assay with Egr-1 overexpression. All authors
reviewed and approved the final version for publication.

3.1. Abstract
Resveratrol, a dietary phytoalexin readily available in the diet, is reported to possess
anti-tumorigenic properties in several cancers, including colorectal cancer. However, the
underlying mechanism(s) involved is not completely understood. In the present study, we
investigated the effect of resveratrol treatment on gene modulation in human colorectal
cancer cells and identified activating transcription factor 3 (ATF3) as the most highly
induced gene after treatment. We confirmed that resveratrol up-regulates ATF3 expression,
both at the mRNA and protein level, and showed resveratrol involvement in ATF3
transcriptional regulation. Analysis of the ATF3 promoter revealed the importance of early
growth response-1 (Egr-1; located at -245 to -236) and Krüppel-like factor 4 (KLF4; located
at -178 to -174) putative binding sites in resveratrol-mediated ATF3 transactivation.
Specificity of these sites to the Egr-1 and KLF4 protein was confirmed by electrophoretic
mobility shift and chromatin immunoprecipitation assays. Resveratrol increased Egr-1 and
KLF4 expression, which preceded ATF3 expression, and further suggests Egr-1 and KLF4
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involvement in resveratrol-mediated activity. We provide evidence for Egr-1 and KLF4
interaction in the presence of resveratrol, which may facilitate ATF3 transcriptional
regulation by this compound. Furthermore, we demonstrate that induction of apoptosis by
resveratrol is mediated, in part, by increased ATF3 expression. Taken together, these results
provide a novel mechanism by which resveratrol induces ATF3 expression and represent an
additional explanation of how resveratrol exerts its anti-tumorigenic effects in human
colorectal cancer cells.

3.2. Introduction
Current research suggests that various dietary phytochemicals function as
chemopreventive and/or adjuvant chemotherapeutic agents, adding to the paradigm that a diet
high in fruit and vegetable content confers protection against chronic disease (3). One such
phytochemical is resveratrol (3, 4’, 5-trihydroxystilbene), a naturally occurring phytoalexin
readily available in the diet and to which a plethora of health-promoting effects have been
ascribed (4). Resveratrol has elicited much attention as a potential anticancer agent since the
inhibitory effect of this compound on carcinogenic processes was first reported in 1997 (5).
Subsequently, numerous studies have illustrated the anti-proliferative effect of resveratrol on
cancer cells, which is believed attributable to induction of cell cycle arrest in the G1/S or
G2/M phase and induction of apoptosis and related proteins (44, 45). More importantly,
treatment with resveratrol inhibited tumorigenesis in vivo (7, 82, 159). However, the underlying
mechanism(s) involved in the anti-tumorigenic/anti-carcinogenic activities of resveratrol
remain poorly defined due to its capacity to modulate a multitude of signaling pathways.
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Activating transcription factor 3 (ATF3), a member of the ATF/CREB family of bZIP
transcription factors, is characterized as a stress-inducible or adaptive response gene (121).
Much controversy exists as to the physiological role of ATF3 in tumorigenesis, and ATF3 is
demonstrated to a positive and/or negative modulator of tumor progression. Recently, a
dichotomous role was reported for ATF3 in cancer development; the authors concluded its
role as a tumor suppressor or oncogene is largely dependent on cellular context and extent of
malignancy (122). However, several lines of evidence suggest that ATF3 may function as a
tumor suppressor gene in colorectal carcinogenesis. Firstly, ATF3 expression is markedly
reduced in cancer tissues, including colon, when compared to normal adjacent tissue (160, 161).
Secondly, ATF3 overexpression is demonstrated to elicit a number of cellular responses.
These include (1) the induction of cell cycle arrest with concomitant inhibition of
proliferation (162), (2) induction of apoptosis in vitro and in vivo (155, 163-165), inhibition of
invasion and associated genes (166-168), and retardation of tumor formation in vivo (163, 168).
Finally, ATF3 is reported to mediate or enhance induction of apoptosis by compounds
demonstrated to possess antitumor and anticancer properties (130, 155, 169-171). Thus, it is
believed that ATF3 plays an anti-tumorigenic and anti-carcinogenic role in colorectal cancer.
In the study described here, we examined the effect of resveratrol treatment on gene
modulation in HCT-116 human colorectal cancer cells. We identified ATF3 as the most
highly induced gene after treatment and sought to investigate the transcriptional mechanism
and biological consequence of ATF3 expression in response to resveratrol. Here, we report
that early growth response-1 (Egr-1) and Krüppel-like factor 4 (KLF4) mediates ATF3
transactivation by resveratrol. We show Egr-1 and KFL4 interaction in the presence of
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resveratrol, which may facilitate ATF3 transcriptional regulation by this compound.
Furthermore, we demonstrate induction of apoptosis by resveratrol is mediated, at least in
part, by ATF3.

3.3. Results
3.3.1. Effect of Resveratrol on Gene Expression in HCT-116 Cancer Cells
The mechanism(s) underlying the anti-tumorigenic properties of resveratrol in
colorectal cancer remain mostly unclear. To investigate how resveratrol alters gene
expression in colorectal cancer cells, microarray analysis was performed using HCT-116
cells treated with resveratrol (100 μM). Among the genes up-regulated by the treatment,
ATF3 was identified as most highly induced (Table 3.1). We confirmed resveratrol-induced
ATF3 transcript using reverse transcription PCR (Figure A.1). The alteration of mRNA
transcripts of five additional genes (HO-1, DKK1, NAG-1, Nur77, and PDE4B) by resveratrol
was also confirmed, each of which are suggested to play a role in tumorigenesis (172-176).
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Table 3.1. Alteration of gene expression profiles of HCT-116 colorectal cancer cells by
resveratrol (100 μM). HCT-116 human colorectal cancer cells were treated with resveratrol
(100 μM) for 24 h and microarray analysis was performed. The top 13 up- and downregulated genes are listed.
Gene Symbol
ATF3
MTHFD2
HMOX1
PLAB
ASNS
S100A2

C20orf97
SULF2
CNK
FUS
DKK1
HERPUD1
NR4A1

NR2F1
HNRPA2B1
HMGA2
HAIK2
PRKACB
WNT16
PDE4B
SCG2
GPR110
VSNL1
DKFZP434P1735
CPO
KITLG

Gene Name
Activating transcription factor 3
Methylenetetrahydrofolate (NAD-dependent) 2,
Methenyltetrahydrofolate cyclohydrolase
Heme oxygenase 1 (HO-1)
Macrophage inhibitory cytokine 1 (NAG-1)
Asparagine synthase
Homo sapiens S100 calcium binding protein A2,
mRNA
Protein with high similarity to neuronal cell death
Inducible Putative Kinase
Member of the sulfatase family
Cytokine inducible kinase
RNA-binding protein FUS
Dickkopf homolog 1
Homocysteine-inducible endoplasmic reticulum stressinducible ubiquitin-like domain member 1
Nuclear receptor subfamily 4 group A member 1
(Nur77)
Homo sapiens nuclear receptor subfamily 2, group F,
member 1 (NR2F1), mRNA
Heterogenous nuclear ribonucleoprotein A2/B1
High-mobility group (nonhistone chromosomal)
protein isoform I-C
Member of the intermediate filament family, has
moderate similarity to keratin 19 (human KRT19)
cAMP dependent protein kinase catalytic subunit beta
Wingless-type MMTV integration site family member
16
Phosphodiesterase 4B
Secretogranin II (chromogranin C)
Member of the secretin family of G protein-coupled
receptors
Visinin-like Protein 1
Protein containing 10 armadillo/beta-catenin repeats,
weak similarity to S. cerevisiae Vac8p
Coproporphyrinogen oxidase
Stem cell factor, ligand of KIT tyrosine kinase receptor
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Accession No.
I_929428

Fold
Change
20.37

I_939586
I_961390
I_966585
I_930098
NM_005978.2

13.57
13.13
12.59
10.56
9.88

I_961961
I_962934
I_964814
I_965527
I_932501

8.93
8.23
7.80
7.78
7.47

I_959712
I_932430

7.16
7.13

NM_005654.2
I_930777

-3.46
-3.47

I_963472

-3.48

I_958778
I_931783
I_929920

-3.65
-3.69
-3.77

I_929286
I_928496

-3.79
-3.81

I_957588
I_940805

-3.98
-4.16

I_931567
I_956835
I_944208

-4.26
-4.54
-5.04

3.3.2. Resveratrol Increases ATF3 Expression in Cancer Cells
We next determined whether resveratrol increases ATF3 expression at the protein
level. As shown in Figure A.2A and A.2B, resveratrol increased ATF3 in a concentrationand time-dependent manner in HCT-116 cells. Furthermore, increased ATF3 expression was
observed in both colorectal (Figure A.2C) and non-colorectal (Figure A.2D) cancer cells
after treatment; however, we did not observe ATF3 induction in LoVo colorectal and
SqCC/Y1 head and neck cancer cells. Absence of ATF3 induction by resveratrol in these
cells is most likely due to high endogenous expression of ATF3 (LoVo) or the lack of proper
signaling pathway(s) needed for ATF3 increase by resveratrol (SqCC/Y1). Because
resveratrol increased ATF3 expression at the mRNA and protein level, we sought to
characterize ATF3 as a molecular target of this compound at the transcription level.

3.3.3. Egr-1 and KLF4 are involved in Resveratrol-Induced ATF3 Expression
To identify the transcriptional binding site(s) responsible for resveratrol-mediated
ATF3 expression, HCT-116 cells were transfected with different promoter constructs
spanning the -1850 to +34 bp promoter region (Figure A.3A). Resveratrol treatment resulted
in a significant increase in ATF3 promoter activity for all reporter constructs; however, the
greatest induction was observed within the -514 and +34 bp region, suggesting that a major
response element(s) may be present. This region was further analyzed using three
independent transcription factor search engines (Genomatix-MatInspector, TFSearch, and
Transcription Element Search System) and five possible factors were commonly identified:
p53, Sp1, Egr-1, KLF4, and ATF/CREB (Figure A.3B).
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To investigate the role of identified cis-acting elements in resveratrol-mediated
transcriptional regulation of ATF3, co-transfection experiments were performed utilizing
expression vectors of the aforementioned factors and ATF3 promoter constructs as indicated
(Figure A.4). Expression of each vector, with the exception of ATF3, resulted in increased
pATF3 -514/+34 luciferase activity after resveratrol treatment compared to pcDNA3.1 empty
vector control (Figure A.4A). Interestingly, cells over-expressing KLF4 and Egr-1showed
the greatest increase in resveratrol-induced ATF3 promoter activity, resulting in a 4.1- and
4.3-fold induction, respectively. A similar pattern was observed for the -132 to +34 bp
region (Figure A.4B); however, co-transfection of these expression vectors with pATF3 84/+34 reporter construct had no effect on promoter activity after treatment (Figure A.4C).
Of note, suppression of ATF3 promoter was observed in cells with ATF3 overexpression,
consistent with its role as a negative self-regulator (177). These results identify putative
resveratrol response elements located within the -514 and -84 bp region of the ATF3
promoter and suggest that both Egr-1 and KLF4 may play a role in ATF3 regulation by
resveratrol.
To clarify the importance of Egr-1 and KLF4 in resveratrol-mediated activation of
ATF3, internal deletion clones lacking the Egr-1 and KLF4 binding sites were generated and
transfected into HCT-116 cells. Deletion of Egr-1 or KLF4-A binding site markedly reduced
ATF3 promoter activity in response to resveratrol treatment when compared to wild type
(Figure A.5A). Deletion of the KLF4-B binding site did not change resveratrol-induced
transactivation. Furthermore, because deletion of binding sites corresponding to either Egr-1
or KLF4-A resulted in a significant decrease in resveratrol-induced promoter activity, a
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deletion clone lacking both these sites was generated. Resveratrol-induced activity was
dramatically reduced in cells transfected with the double deletion promoter construct
compared to wild type (Figure A.5A). Moreover, suppression of either endogenous Egr-1 or
KLF4 decreased ATF3 expression in the presence of resveratrol (Figure A.5B), confirming
that both Egr-1 and KLF4 contribute to resveratrol-induced ATF3 expression.

3.3.4. Egr-1 and KLF4 bind to the ATF3 Promoter
To determine whether Egr-1 and KLF4 bind to the ATF3 promoter, EMSA was
performed using biotin-labeled oligonucleotides containing 1-2 copies of the corresponding
promoter binding site. First, we examined the effect of resveratrol on promoter binding by
these factors using nuclear extracts prepared as described in Chapter 2. Pre-incubation of
resveratrol-treated nuclear extracts with Egr-1 and KLF4 oligonucleotides resulted in
DNA/protein complex formation that was competed out with addition of 10X and 100X
molar excess of unlabeled wild type oligonucleotides (Figure A.6, left, lanes 3-4), whereas
pre-incubation with unlabeled mutant oligonucleotides had no affect on DNA/protein
complex formation (Figure A.6, left, lanes 5-6). This suggests that both Egr-1 and KLF4 are
able to bind to the ATF3 promoter. Secondly, we verified the specificity of the binding sites
for Egr-1 and KLF4 using in vitro translated proteins mixed with their respective
oligonucleotides. As shown in Figure A.6, both Egr-1 and KLF4 bind to their specific
binding sites as evidenced by the formation of shift bands that were competed out by 10X
and 100X molar excesses of unlabeled oligonucleotides (Figure A.6, right, lanes 10-11).
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Addition of mutant oligonucleotides did not affect binding of Egr-1 or KLF4 to the ATF3
promoter (Figure A.6, left, lanes 12-13).
Finally, a chromatin immunoprecipitation (ChIP) assay was performed to further
confirm that Egr-1 and KLF4 bind to the ATF3 promoter after resveratrol treatment. As
shown in Figure A.7, immunoprecipitation of the chromatin/protein complex with Egr-1 and
KLF4 resulted in the enrichment of these proteins at the ATF3 promoter (left) and the
visualization of a 184 bp band of the amplified promoter (right). In conjunction with results
described above, these data suggest that both Egr-1 and KLF4 bind to the ATF3 promoter and
activate transcription in the presence of resveratrol. However, Egr-1 may contribute more to
resveratrol-induced ATF3 expression, since resveratrol enhances Egr-1 binding capacity to
the ATF3 promoter.

3.3.5. de novo Synthesis is required to Increase ATF3 Expression
We then examined the requirement of de novo protein synthesis for resveratrolmediated ATF3 expression because Egr-1 and KLF4 appear to be required for induction of
ATF3. HCT-116 cells were treated with CHX and resveratrol (50 μM). In the presence of
CHX, resveratrol was unable to increase ATF3 expression, suggesting that ATF3 increase by
resveratrol is dependent on de novo protein synthesis (Figure A.8A). We next determined
whether resveratrol could alter expression of Egr-1 and KLF4. Resveratrol treatment
increased Egr-1 and KLF4 mRNA transcript (Figure A.8B) and protein expression (Figure
A.8C). It should be noted that induction of both Egr-1 and KLF4, which occurred at
approximately 1 h of treatment and continued until 3 h, preceded that of ATF3, which began
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after 6 h. Together, these results are compatible with the notion that observed increase in
ATF3 expression by resveratrol requires synthesis of Egr-1 and KLF4.

3.3.6. Egr-1 and KLF4 Interaction Facilitates Resveratrol-Mediated ATF3 Induction
Because both Egr-1 and KLF4 are involved in resveratrol-mediated activity, we
examined whether these factors coordinate or compete in ATF3 expression. HCT-116 cells
were co-transfected with pATF3 -514/+34 and expression vectors and treated as described.
As observed previously, both Egr-1 and KLF4 increased ATF3 promoter activity in the
presence of resveratrol (Figure A.9). Moreover, co-expression of these factors resulted in
enhanced transactivation of ATF3 at both the basal level and after resveratrol treatment.
Previous studies have shown interaction between two Zn finger transcription factors
(178)

and that this interaction facilitates transcriptional activation (179). To investigate the

potential for Egr-1 and KLF4 interaction, mammalian-2-hybrid assay was performed.
Briefly, Egr-1 and KLF4 were cloned into the pM vector containing a DNA binding domain
and pVP16 vector containing an activation domain, respectively. These constructs were then
co-transfected with the luciferase reporter construct pG5Luc into HCT-116 cells and treated
with resveratrol. If there is interaction, luciferase activity should be detected resulting from
the formation of a complex between the two vectors and subsequent binding to the DNA
binding domain of the pG5Luc vector; this results in pG5Luc promoter activation.
As shown in Figure A.10A, Egr-1 and KLF4 bind to each other at the basal level and
this interaction is enhanced after resveratrol treatment (7.2-fold vs. 52-fold increase).
Increased Egr-1 and KLF4 interaction was also observed after DIM treatment. DIM
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increases ATF3 expression (130). To exclude the potential for direct binding of pVP16/KLF4
to the DNA binding domain of the pM empty vector, the vectors were co-transfected and
mammalian-2-hybrid assay was performed; no interaction was detected, allowing one to infer
the interaction of Egr-1 and KLF4 is genuine (data not shown).
We next sought to tentatively identify the region that may facilitate this interaction
and generated pM/Egr-1 deletion constructs lacking (1) 133-159 aa of the activation domain
and (2) 370-395 aa of the Zn finger domain (Figure A.10B, top). Both the partial deletion of
the activation domain and deletion of the second Zn finger domain of Egr-1 resulted in
decreased interaction with KLF4 (Figure A.10B, bottom). We confirmed mammalian-2hybrid assay by Egr-1 and KLF4 immunoprecipitation experiments (Figure A.11). Egr-1
and KLF4 are co-immunoprecipitated with either antibody, whereas Egr-1 deletion clones
had diminished binding capacity to KLF4. Together, these data suggest that Egr-1 and KLF4
physically interact, which is increased by resveratrol, and that the Egr-1 activation or Zn
finger domain may mediate this interaction.

3.3.7. Knockdown of ATF3 Suppresses Resveratrol-Induced Apoptosis
We have identified ATF3 as a molecular target of resveratrol; however, the biological
consequence(s) of ATF3 induction by resveratrol in colorectal tumorigenesis is unknown.
As described in the introduction, pharmaceuticals and phytochemicals’ increase of ATF3
mediated or enhanced apoptosis by these compounds (130, 155, 169-171). To determine if this is
true for resveratrol, we measured caspase-3/7 enzyme activity for resveratrol-treated HCT116 and HT29 cancer cells. As depicted in Figure A.12A, resveratrol treatment increased
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apoptosis in a dose-dependent manner. Furthermore, ATF3 overexpression in these cells also
increased apoptosis, which depend on caspase activation (Figure A.12B). Together, these
data suggest that both resveratrol and ATF3 expression induce apoptosis in our model
system. Next, to investigate whether resveratrol-induced apoptosis is mediated by ATF3,
ATF3 expression was knocked down by siRNA followed by resveratrol treatment for 24 h.
As depicted in Figure A.12C, knockdown of ATF3 significantly abrogated caspse-3/7
enzymatic activity by resveratrol. This suggests that ATF3 plays a role in resveratrolinduced apoptosis.

3.3.8. Egr-1 and KLF4 Transactivate ATF3 Independent of Resveratrol
Results herein suggest Egr-1 and KLF4 involvement in resveratrol-mediated ATF3
activation. To determine if these transcription factors are able to affect ATF3 transcription
individually, promoter activity was measured after co-transfection with Egr-1 or KLF4
expression vectors. As shown in Figure A.13, both Egr-1 and KLF4 are able to increase
ATF3 promoter activity. Of note, the minimum region required for Egr-1 or KLF4-mediated
induction may be independent of that shown to be required for resveratrol (see Figure A.4).
For Egr-1, the -1850 bp of the ATF3 promoter showed the highest luciferase activity and for
KLF4, this region lies within the -1420 bp of the ATF3 promoter. This result suggests that
binding sites of Egr-1 and KLF4 within the -514 bp of the ATF3 promoter play an important
role in resveratrol-induced ATF3 expression; however, Egr-1 and KLF4 also increase ATF3
promoter activity in the absence of resveratrol through different promoter regions.
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3.3.9. Posttranscriptional Regulation of ATF3 by Resveratrol as an Alternate Regulatory
Pathway
Posttranscriptional control of eukaryotic gene expression provides an alternative
regulatory process(s) to control protein abundance (180). To determine if such processes
account for ATF3 regulation by resveratrol, ATF3 mRNA stability was measured as
described in Chapter 2. Briefly, HCT-116 cells were pre-treated with resveratrol (50 μM)
for 24 h followed by actinomycin D, to terminate transcription, for the indicated times. As
depicted in figure A.14, resveratrol stabilized ATF3 mRNA and increased the half-life from
approximately 7 h to 14 h, suggesting that posttranscriptional control of ATF3 by resveratrol
may account for the observed increase in ATF3 protein level.

3.4. Discussion
Resveratrol, a dietary phytoalexin readily available in the diet, has garnered much
attention as a potential chemopreventive and/or chemotherapeutic agent. Numerous studies,
utilizing in vitro and in vivo model systems, have illustrated resveratrol’s capacity to inhibit
the stages of carcinogenesis (initiation, promotion, and progression) and modulate a
multitude of signaling pathways associated with cellular growth and division, apoptosis,
angiogenesis, and metastasis (6). However, the underlying mechanism(s) involved in the antitumorigenic/anti-carcinogenic activities of resveratrol, especially in colorectal cancer, are
complex and remain poorly defined. The present study sought to investigate the effect of
resveratrol on gene modulation in HCT-116 human colorectal cancer cells in order to identify
a novel target that may mediate the anticancer activities of this compound and determine the
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mechanism involved in its regulation. Our data identified ATF3 as the most highly
expressed gene after resveratrol treatment (Table 3.1) and showed ATF3 was indeed upregulated at both the mRNA (Figure A.1) and protein (Figure A.2) level by the compound.
We also demonstrate increased stability of the ATF3 transcript by resveratrol, which may
contribute to the observed ATF3 expression in colorectal cancer cells highly induced by
resveratrol (Figure A.14).
Recently, a dichotomous role in cancer development was reported for ATF3; the
authors of that study demonstrated both a tumor suppressive (early-stage tumorigenesis) and
oncogenic (late-stage tumorigenesis) role in breast cancer cell lines derived from similar
genetic backgrounds with varying degrees of malignancy (122). Similarly, a duality of
function was demonstrated for ATF3 in cancer studies of the prostate (164, 181) and of the colon
(168, 182)

. Yet, as described in the introduction, several lines of evidence suggest ATF3

behaves as a negative regulator of tumorigenesis. For example, ATF3 expression is induced
by several compounds demonstrated to possess anti-tumorigenic properties (130, 155, 169-171).
The results presented here add to the list of compounds that induce ATF3 with mechanistic
data.
To elucidate the molecular mechanism by which resveratrol induced ATF3
expression, the promoter region spanning -1850 to +34 bp was assessed by luciferase assay
in response to resveratrol. We found that resveratrol transactivated the ATF3 promoter and
identified putative response elements located within the -514 to -84 bp (Figure A.3). Cotransfection experiments suggested the involvement of the transcription factors Egr-1 and
KLF4 (Figure A.4). Egr-1 and KLF4 participation in resveratrol-mediated activation of
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ATF3 was confirmed by deletion (Figure A.5A) and knockdown (Figure A.5B)
experiments. Interestingly, deletion of both Egr-1 and KLF4-A binding sites from the ATF3
promoter dramatically reduced transactivation by resveratrol, indicating that the combination
of these two factors is important for ATF3 transcriptional regulation by resveratrol. Yet, we
cannot exclude the involvement of other cofactors, such as p53 and Sp1 (Figure A.4), in the
compound’s-mediated activity. ATF3 regulation by p53 is documented in the literature (183)
and p53 is increased by resveratrol (139), which suggests a potential role for p53 in resveratrolmediated ATF3 activation. Furthermore, Sp1 was recently demonstrated to regulate ATF3
expression in colon cancers cells (184); however, we did not observe Sp1 induction by
resveratrol (data not shown). Here, we focused on Egr-1 and KLF4 because both increased
resveratrol-mediated ATF3 activation and were modulated by the compound. In addition, as
shown in Figure A.13, both Egr-1 and KLF4 activate ATF3 promoter activity in the absence
of resveratrol, indicating the pleiotropic role of both Egr-1 and KLF4 in ATF3 transcriptional
regulation. Because resveratrol can increase Egr-1 and KLF4 expression and transcription
activity, one could speculate that observed anticancer properties of resveratrol may be
facilitated through either an Egr-1-mediated or KLF4-mediated mechanism.
Egr-1 and KLF4 belong to a family of immediate early response genes whose
expression is transiently induced in response to various environmental stimuli (185, 186). Each
encode a transcription factor containing three carboxyl C2H2 type zinc finger motifs that
coordinate the expression of genes associated with cell proliferation, differentiation, and
apoptosis (186-188). In addition, Egr-1 and KLF4 are suggested to act as master regulatory
proteins involved in cell fate decisions (189, 190). Nonetheless, as with ATF3, much
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controversy exists as to the role of Egr-1 and KLF4 in cancer development and their
biological function appears largely context dependent. Several studies have demonstrated
that Egr-1 and KLF4 expression facilitate tumor progression in vivo (191-194); however, there is
ample evidence supporting a tumor suppressive role for both transcription factors (195-202).
Our data indicates that Egr-1 and KLF4 are able to bind to the ATF3 promoter
(Figure A.6 and A.7) and that their biosynthesis is necessary for resveratrol-mediated
activity (Figure A.8). Moreover, these transcription factors cooperate in ATF3
transactivation (Figure A.9). From this, two inferences can be made: (1) synergism between
Egr-1 and KLF4 promote ATF3 activation, which is enhanced after resveratrol treatment and
(2) interaction between the two facilitate transcriptional regulation by ATF3 by the
compound. Indeed, the results ascertained by mammalian 2-hydrid assay and
immunoprecipitation experiments corroborate Egr-1 and KLF4 interaction (Figure A.10 and
A.11, respectively). Furthermore, resveratrol and DIM increased Egr-1 and KLF4
interaction. These results imply that a similar mechanism may contribute to induction of
ATF3 by these and possibly other phytochemicals that increase ATF3 expression.
Current research suggests the importance of C2H2 type zinc finger domains in
protein-protein interaction (203, 204). Consistently, we found the zinc finger domain of Egr-1
as a possible region responsible for interaction with KLF4. Our data also identified the
activation domain of Egr-1 as responsible for mediating the interaction with KLF4 (Figure
A.10 and A.11). To our knowledge, this is the first report identifying the involvement of the
activation domain in protein-protein interaction of two zinc finger transcription factors.
Thus, the activation domain contributes not only to the initiation of transcription but also
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contribute to protein-protein interactions with other transcription factors; interaction via the
activation domain or the zinc finger domain leads to enhanced compound-induced
transcription.
Results identify ATF3 as a molecular target of resveratrol whose regulation is
mediated by Egr-1 and KLF4 interaction. However, the biological consequence(s) of ATF3
induction by the compound is unknown in colorectal tumorigenesis. To answer this question,
we examined induction of apoptosis by resveratrol and ATF3 in colorectal cancer cells
because, as described, ATF3 mediates or enhances apoptosis by compounds with known
antitumor activities. As depicted in Figure A.12, resveratrol and ATF3 overexpression
increased caspase 3/7 enzymatic activity in HCT-116 and HT29 cancer cells. Furthermore,
knockdown of ATF3 expression resulted in reduced apoptosis by resveratrol and suggests
that ATF3 plays a role in resveratrol-induced apoptosis. However, further study is required
to determine whether ATF3 contributes to resveratrol anticancer effects in vivo.
In conclusion, we found the stress-inducible and/or adaptive response gene ATF3 as
the most highly induced gene after resveratrol treatment in human colorectal cancer cells.
Here, we report for the first time the involvement of resveratrol in the transcriptional
regulation of ATF3 and that the C2H2 type zinc finger transcription factors Egr-1 and KLF4
mediate this regulation. We demonstrate that Egr-1 and KLF4 interact with each other in the
presence of resveratrol, which may facilitate ATF3 transcriptional regulation by this
compound. Furthermore, increased ATF3 expression by resveratrol facilitates induction of
apoptosis by the compound (Figure. 3.1).
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Figure 3.1. Schematic diagram of ATF3-mediated resveratrol action in colorectal cancer cells.
Egr-1 and KLF4 are involved in the induction of ATF3 by resveratrol. Resveratrol increases the
expression of both Egr-1 and KLF4; this in turn results in the interaction of Egr-1 with KLF4,
potentially facilitated by the activation or zinc finger domain of Egr-1, leading to promoter binding
and transactivation of ATF3. Increased ATF3 expression results in increase of apoptosis in colorectal
cancer cells. Alternatively, both Egr-1 and KLF4 activate ATF3 promoter in the absence of
resveratrol.
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Chapter 4:
Role of Post-translational Modification of Egr-1 in
Resveratrol-Mediated Anticancer Activity
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4.1. Abstract
Resveratrol, a dietary phytochemical readily available in the diet, has elicited much
attention as a potential chemopreventive and/or chemotherapeutic agent in several cancers,
including colorectal cancer. However, the underlying mechanism(s) involved is not
completely understood. Recently, we identified the transcription factor early growth
response-1 (Egr-1) as a molecular target of resveratrol in colorectal cancer cells that is
involved in resveratrol-mediated anticancer effects. In the present study, we sought to
investigate the role of the sirtuin 1 (SIRT1) deacetylase, which is suggested to account for the
observed anticancer activities of resveratrol, in increased Egr-1 transcriptional activity by the
phytochemical. Here, we report a SIRT1-independent mechanism for resveratrol-induced
Egr-1 activity due to decreased SIRT1 phosphorylation, resulting in suppression of SIRT1
deacetylase activity. We show that acetylation contributes to Egr-1-induced nonsteroidal
anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) expression through increased
Egr-1 binding to the NAG-1 promoter and enhanced transactivation. Thus, acetylation of
Egr-1 plays an important role in resveratrol-mediated transactivation of NAG-1. Taken
together, these results provide a novel mechanism by which resveratrol induces Egr-1
transcriptional activity that is independent of SIRT1 expression.

4.2. Introduction
Resveratrol (3, 4’, 5-trihydroxystilbene), a naturally occurring dietary phtyoalexin to
which a plethora of health-promoting benefits have been ascribed (4), has elicited much
attention as a potential cancer chemopreventive and/or chemotherapeutic agent since the
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inhibitory effect of the compound on carcinogenesis was first reported by Jang et al. (5).
Subsequently, numerous studies have illustrated the anti-proliferative effect of resveratrol on
cancer cells, which is attributable to induction of cell cycle arrest and/or apoptosis and
related proteins (45, 69, 205). Treatment with resveratrol has also been shown to result in
induction of autophagocytosis and senescence in ovarian and colorectal cancer cells,
respectively (61, 206). Furthermore, resveratrol treatment resulted in the inhibition of
angiogenic, invasive, and metastatic factor release (6) as well as inhibition of tumorigenesis in
vivo (67, 159, 207). However, the underlying mechanism(s) involved in the anticancer activities
of resveratrol remain poorly defined.
The seven member mammalian sirtuin family of histone deacetylases have gained
considerable attention as novel targets for the treatment of chronic diseases, such as cancer
(208)

. Sirtuin 1 (SIRT1), a NAD-dependent type III histone and non-histone deacetylase, is

reported to play a critical role in various physiological and pathological conditions, including
carcinogenesis (208). Yet, as to whether the inhibition or activation of SIRT1 contributes to
the development of cancer is debatable due to its involvement in the inhibition of key tumor
suppressor and proto-oncogene proteins (209). In colorectal carcinogenesis, SIRT1 expression
is demonstrated to inhibit tumor formation and proliferation in vitro and in vivo (210, 211).
Moreover, resveratrol is identified as a potent activator of SIRT1 (212) and activation of
SIRT1 by resveratrol reduces tumorigenesis in vivo (213). Furthermore, Boily et al. (214)
suggest that activation of the deacetylase by the phytoalexin is required, at least partially, for
the observed anticancer activities of resveratrol.
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Previously, we identified the transcription factor early growth response-1 (Egr-1) as
a molecular target of resveratrol in colorectal cancer cells and demonstrate Egr-1’s role in
resveratrol-mediated activating transcription factor 3 (ATF3) activation and subsequent
anticancer effects (215). In the study described here, we sought to investigate the role of
SIRT1 in increased Egr-1 transcriptional activity by the phytoalexin. Here, we demonstrate a
SIRT1-independent mechanism for resveratrol-induced Egr-1 activity and suggest the
importance of acetylation, at least partially, in this response.

4.3. Results
4.3.1. Increased Egr-1 Activity by Resveratrol is SIRT1 Independent
Recently, Boily et al. (214) suggested that the anticancer effects of resveratrol are
partially dependent on the presence of SIRT1 protein. Thus, to investigate the role of SIRT1
in resveratrol-induced Egr-1 transcriptional activity, we first examined the effect of
resveratrol on SIRT1 phosphorylation status in HCT-116 human colorectal cancer cells.
Current research suggests SIRT1 phosphorylation, particularly at serine residues 27 and 47,
is associated with increased deacetylase activity (216-218). As demonstrated in Figure B.1A
and B.1B, resveratrol treatment did not alter total SIRT1 protein expression; however, we
observed a dramatic decrease in SIRT1 phosphorylation at serine 27 but not serine 47, which
occurred in a concentration- and time-dependent manner (Figure B.1A and B.1B,
respectively).
Next, we determined if SIRT1 could affect resveratrol-induced Egr-1 transcriptional
activity. To accomplish this, we performed co-transfection experiments using the pEBS14luc
reporter construct, which contains four copies of the Egr-1 binding site (EBS) and is used as
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an indirect measure of transcriptional activity. HCT-116 cancer cells were co-transfected as
indicated in Figure B.2A and treated with resveratrol (50 μM) for 24 h. As shown in Figure
B.2A, resveratrol increased the luciferase activity of pEBS14luc-transfected cells in the
presence of endogenous and exogenous Egr-1 levels (pBABE). Moreover, SIRT1
overexpression had no effect on resveratrol-induced pEBS14luc activity. A similar effect
was observed with pEgr-1 -1260/+35 reporter construct (Figure B.2B). Taken together,
these results suggest that (1) resveratrol decreases SIRT1 phosphorylation, presumably
resulting in suppression of SIRT1 deacetylase activity, and (2) resveratrol increases Egr-1
transcriptional activity independent of SIRT1 activation.

4.3.2. Egr-1 aDaa Mutation Diminishes Resveratrol-Induced Egr-1 Activity
Acetylation of Egr-1 is reported to result in the preferential activation of Egr-1 prosurvival target genes in prostate cancer (219); Egr-1 is suggested to behave as an oncogene in
these cancers. However, in our model system, Egr-1 facilitates the anticancer activities of
resveratrol (215); therefore, we hypothesize that acetylation of Egr-1, through inhibition of
SIRT1 deacetylase activity (Figure B.1), may be required for observed resveratrol-induced
expression mediated by the transcription factor. To test this hypothesis, we first generated an
acetylation deficient Egr-1 construct as described in Chapter 2 based upon the identified
putative acetylation site (KDKK) within Egr-1’s weak transactivation domain (see Figure
B.3 for amino acid sequence (219)).
We next determined whether resveratrol increased Egr-1 acetylation and whether it
occurred at the KDKK site. HCT-116 cells were transiently transfected with either control or
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Egr-1 (WT and acetylation deficient, aDaa) constructs. Culture of transfected cells with
resveratrol (50 μM) for 2 h resulted in increased acetylation of both endogenous and
exogenous Egr-1 as demonstrated using an anti-acetylated lysine antibody (Figure B.4A).
However, Egr-1 acetylation by resveratrol was not observed in the acetylation deficient Egr-1
aDaa construct (Figure B.4A). Furthermore, resveratrol-induced Egr-1 transcriptional
activity was diminished in the presence of the acetylation deficient construct (Figure B.4B).
These results suggest that resveratrol acetylates Egr-1 and that this posttranslational
modification, at least partially, is important in resveratrol-induced Egr-1 transcriptional
activity.

4.3.3. Acetylation Contributes to Activation of the Egr-1 Target Gene, NAG-1
As previously described, Egr-1 acetylation status is associated with preferential
transactivation of either survival-related (acetylated) or apoptosis-related (unacetylated) Egr1 gene targets in prostate cancers (219); yet, in colorectal cancer, acetylation of Egr-1 may
facilitate anti-proliferative and/or pro-apoptotic gene activation. We therefore studied three
known Egr-1 target genes to determine whether acetylated Egr-1 produced a different result
compared to unacetylated Egr-1. An expression study was performed in resveratrol-treated
HCT-116 cancer cells by measuring protein (Figure B.5A) and mRNA (Figure B.5B) levels
of activating transcription factor 3 (ATF3), NSAID-activated gene-1 (NAG-1), and p53 after
transfection with Egr-1 WT or Egr-1 aDaa. Figure B.5A shows that resveratrol strongly
induced the expression of the Egr-1 target genes examined (lanes 2, 6, and 10). Similar
results were observed in the presence of Egr-1 WT overexpression (lanes 5 and 6).
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However, Egr-1 aDaa was only less active in inducing NAG-1 expression when compared to
WT in vehicle- and resveratrol-treated HCT-116 cancer cells (Figure B.5A, lanes 5 and 6 vs.
lanes 9 and 10). Decreased Egr-1 aDaa induced NAG-1 mRNA expression was also
observed in control- and resveratrol-treated HCT-116 cancer cells (Figure B.5B).
Acetylation of non-histone proteins is suggested to alter the DNA binding affinity of
transcription factors for their target gene (220). Because resveratrol treatment increases Egr-1
acetylation and subsequent expression of the Egr-1 target gene NAG-1, we sought to
determine if this increased expression was due to increased Egr-1 binding affinity to the
NAG-1 promoter resulting in its transcriptional activation by Egr-1. We performed a
chromatin immunoprecipitation (ChIP) assay to examine whether unacetylated Egr-1 (Egr-1
aDaa) had less affinity for the NAG-1 promoter as compared to acetylated Egr-1 (Egr-1 WT).
As shown in Figure B.6A, immunoprecipitation of chromatin/protein complex with Egr-1
resulted in the visualization of a 202-bp band of the amplified NAG-1 promoter.
Interestingly, in Egr-1 aDaa-transfected HCT-116 cancer cells had less promoter binding as
compared to Egr-1 WT-transfected cells for both vehicle- and resveratrol-treated cells. The
observed decrease in Egr-1 aDaa binding affinity for the NAG-1 promoter also resulted in
reduced Egr-1 induced transcriptional activation (Figure B.6B). Taken together, these
results suggest that Egr-1 acetylation, at least partially, contributes to Egr-1-induced NAG-1
expression and to resveratrol-induced Egr-1-mediated NAG-1 expression in our model
system.
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4.4. Discussion
The dietary phytochemical resveratrol has elicited much attention as a putative
anticancer agent; current research demonstrates resveratrol-mediated inhibition of
carcinogenesis and modulation of cancer-associated signal transduction pathways (6). Yet,
despite the identification of molecular targets, the underlying mechanisms that mediate
resveratrol’s anticancer activities remain elusive, especially in colorectal cancer. In this
present study, we sought to investigate the role of SIRT1 in resveratrol-induced Egr-1
transcriptional activity. Our data revealed a SIRT1-independent mechanism for resveratrolinduced Egr-1 activity and suggest the importance of acetylation, at least partially, in this
response.
Recently, it has been suggested that SIRT1 contributes to the anticancer activity(s) of
resveratrol; the authors of that study demonstrate reduced resveratrol-mediated tumor
inhibition (incidence, load, and volume) in SIRT1-null mice as compared to normal using a
two-stage model of skin carcinogenesis (214). Similarly, Wang et al. (213) showed that
activation of SIRT1 by resveratrol could partially inhibit tumor formation attributable to
delayed tumor onset. Moreover, the tumors that developed in resveratrol-treated mice did
not contain SIRT1, thus explaining why resveratrol did not inhibit tumor formation is this
group (213). Based on these studies, one could infer that the inhibitory effect of resveratrol on
carcinogenesis is predicated on SIRT1 activity. Yet, as we demonstrate here, enhanced Egr-1
transcriptional activity by resveratrol occurs in a SIRT1-independent manner (Figure B.1.
and B.2). This contradicts the notion of a SIRT1-dependent component to the anticancer
effects of resveratrol. Recent evidence; however, suggests that resveratrol is not a direct
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activator of SIRT1 (221) and resveratrol inhibition of tumor growth is SIRT1-independent (222).
The results presented here are in agreement with these latest findings.
Acetylation of non-histone proteins at lysine residues is suggested to modulate
protein function (e.g. signal transduction, DNA binding, protein stability, and localization)
(220)

. Furthermore, as in the case of the tumor suppressor p53, acetylation of transcription

factors at lysine residues by the p300/CBP acetyltransferase may increase DNA binding
affinity followed by subsequent transcriptional activation of their target genes (223).
Therefore, inhibition of SIRT1 deacetylase activity by resveratrol may contribute to Egr-1
acetylation and increased Egr-1 transcriptional activity. Indeed, our results suggest that
resveratrol-induced Egr-1 activity is associated with the transcription factor’s acetylation
(Figure B.4). However, the acetyltransferase responsible for Egr-1 acetylation remains to be
identified, although p300/CBP involvement is likely (219).
Egr-1 belongs to a family of immediate early response genes whose expression is
transiently induced in response to various environmental stimuli (185) and is suggested to act
as a master regulatory protein involved in cell fate decisions (189). Several reports indicate
Egr-1 involvement in the activation of the pro-apoptotic proteins ATF3 (155, 156, 215, 224), NAG1 (225-229), and p53 (228, 230, 231). Additionally, Yu et al. (219) reported that acetylation of Egr-1 at
the KDKK motif, within its weak transactivation domain, dictated its role in cell fate
decisions in prostate carcinogenesis. Thus, to determine if Egr-1 acetylation status is
associated with Egr-1 mediated cell fate decisions in our HCT-116 colorectal cancer cell
model, we examined the expression of these three Egr-1 targets. As shown in Figure B.5,
we observed less NAG-1 expression for acetylation deficient Egr-1 aDaa construct-
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transfected HCT-116 colorectal cancer cells as compared to Egr-1 WT-transfected cells.
Decreased NAG-1 expression by the acetylation deficient Egr-1 occurred, presumably,
through decreased NAG-1 promoter binding followed by diminished NAG-1 transactivation
(Figure B.6). However, expression of Egr-1 aDaa had no appreciable effect on ATF3 or p53
expression; this observation may be due to the involvement of other transcription factors in
resveratrol-mediated ATF3 or p53 activation.
In conclusion, we demonstrate here a SIRT1-independent mechanism for increased
Egr-1 transcriptional activity by resveratrol, associated with the inhibition of SIRT1
deacetylase activity (Figure 4.1). The study also demonstrates the importance of acetylation
in resveratrol-induced Egr-1 activity. Acetylation facilitates Egr-1-induced NAG-1
expression through increased Egr-1 binding to the NAG-1 promoter followed by enhanced
transactivation in the presence of resveratrol. Thus, acetylation of Egr-1 plays an important
role in resveratrol-mediated transactivation of NAG-1.
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Figure 4.1. Schematic diagram of the role of resveratrol-induced Egr-1 acetylation in colon
cancer cells. In colorectal cancer, resveratrol increases Egr-1 acetylation through a yet to be
identified acetyltransferase, resulting in increased NAG-1 expression and subsequent induction of
anticancer effects such as apoptosis.
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Chapter 5:
Conclusions and Future Perspectives
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The continued identification of dietary phytochemicals and their related derivatives
with chemopreventive and/or chemotherapeutic activities offers an alternative and
complementary approach to the prevention and treatment of cancers. Studies investigating
the use of these compounds for cancer prevention or as adjuvants to traditional therapies have
revealed several potential benefits: (1) suppression of tumorigenesis and carcinogenesis in
vitro and in vivo, (2) sensitization of cancer cells to drug-induced growth inhibition, and (3)
minimization of adverse effects associated with conventional therapies. Most importantly,
dietary phytochemicals are demonstrated to target multiple signal transduction pathways
involved in cancer development, an important advantage due to the inherent heterogeneity of
cancers.
Resveratrol (3, 4’, 5-trihydroxystilbene), a naturally-occurring phytoalexin, has been
identified in extracts from more than 70 plant species, including grapes (predominant
source), berries, jackfruit, and peanuts (232). Since Jang et al. (5) first identified the inhibitory
effect of resveratrol on carcinogenesis, numerous studies have demonstrated the capacity of
resveratrol to modulate a multitude of signaling pathways associated with cancer
development (see Chapter 1). As a result, we postulate that resveratrol may function as a
potential signaling pathway modulator and it is likely that this collective activity, rather than
just a single effect, plays an important role in the anticancer properties of resveratrol.
However, despite the identification of numerous molecular targets, the underlying
mechanisms involved in the antitumor/anticancer activities of resveratrol, especially in
colorectal cancer, are complex and remain poorly defined. Thus, we sought to investigate the
effect of resveratrol on gene modulation in human colorectal cancer cells in order to identify
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and characterize novel molecular targets that may contribute to observed antitumor activities
of resveratrol. The data presented in Chapter 3 and in Chapter 4 suggest that activating
transcription factor 3 (ATF3) and early growth response-1 (Egr-1), respectively, are novel
molecular targets of resveratrol in colorectal carcinogenesis.
ATF3, a stress-inducible or adaptive response gene, is suggested to function as a
tumor suppressor gene in colorectal carcinogenesis due to its inhibitory effects on tumor cell
proliferation, tumor formation, and invasion (see Chapter 3 for references). Here, we
identify ATF3 as a target of resveratrol that contributes to apoptosis induced by the dietary
phytoalexin in vitro. Furthermore, resveratrol-increased ATF3 expression is mediated
through Egr-1 and Krüppel-like factor 4 (KLF4) interactions, which occurs via the activation
or zinc-finger domain of Egr-1. These findings show, for the first time, the involvement of
resveratrol in the transcriptional regulation of ATF3, mediated by Egr-1 and KLF4, and that
increased ATF3 expression facilitates induction of apoptosis by resveratrol.
Egr-1, characterized as an immediate early response transcription factor, is also
suggested to behave as a tumor suppressor in colorectal cancer (refer to Chapter 3 and
Chapter 4). The data presented in Chapter 4 suggest that increased Egr-1 transcriptional
activity by resveratrol is dependent on the resveratrol-induced posttranslational acetylation of
Egr-1, which is SIRT1-independent in vitro. Thus, resveratrol not only affects Egr-1 at the
level of transcription (Chapter 3), but affects Egr-1 at the level of translation as well. Egr-1
acetylation by resveratrol contributes, at least partially, to Egr-1 induced expression of the
pro-apoptotic protein NAG-1. Again, these findings represent a novel mechanism by which
resveratrol induces Egr-1 transcriptional activity that is independent of SIRT1 expression.
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Yet, in order to identify ATF3 or Egr-1 (and even KLF4) as genuine targets of
resveratrol, we must validate the importance of these proteins in the anticancer activity of
resveratrol in vivo. This can be readily achieved using an azoxymethane-induced model of
colorectal carcinogenesis with ATF3-null (233) and Egr-1-null (234) mice. With this model we
can examine the involvement of ATF3 and Egr-1 in resveratrol-mediated chemoprevention
(administration of resveratrol prior to azoxymethane injection) and chemotherapy
(azoxymethane injection prior to resveratrol administration). It would also be interesting to
examine the role of ATF3 and Egr-1 using APCmin/+ mice, a genetic model that results in
adenoma formation in the small intestine.
Therefore, in addition to the classical approaches to chemotherapy, the role of
resveratrol as an adjuvant therapy to standard cancer treatments should be evaluated. As
discussed, resveratrol is demonstrated to potentiate the cytotoxic effects of known
chemotherapeutic drugs and could alleviate associated adverse effects. Most patients would
readily accept the addition of a low toxicity agent such as resveratrol as adjuvants to
chemotherapy. Additionally, the molecular targets described in Chapter 1 should be
evaluated in an adjuvant setting to determine its contributions to the anticancer benefits of
resveratrol; validation of such targets could identify novel therapeutic targets for the
treatment of cancer and justify the use of resveratrol as an anticancer drug. Moreover, the
identification of the novel molecular targets ATF3 (Chapter 3) and Egr-1 (Chapter 4), and
subsequent validation as a target in vivo, provide an additional explanation of how resveratrol
exerts its anti-tumorigenic and anti-carcinogenic effects in colorectal cancer.
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Figure A.1. Effect of resveratrol on gene expression in HCT-116 cells. (A) HCT-116 cells were
treated with vehicle or resveratrol (Resv) in serum-free media for 24 h. RT-PCR was performed
using specified human primers as described in Chapter 2. GAPDH served as a loading control.
Representative gel pictures of three independent experiments are shown. (B) Gel densitometry results
from three experiments for the respective genes in (A). Values are expressed as fold induction
relative to vehicle-treated cells adjusted to GAPDH. Statistical significance is shown as p < 0.05*
and p < 0.01**.

99

Figure A.2. Resveratrol increased ATF3 expression in cancer cells. Cancer cells were seeded and
grown to 60% to 80% confluence, serum starved overnight, and treated with Resv as indicated in
serum-free media. Protein lysates were harvested and subjected to Western blot analysis using ATF3
and Actin antibodies. (A) HCT-116 cells were treated with 0, 10, 50, and 100 μM Resv for 24 h. (B)
HCT-116 cells were incubated with Resv (50 μM) for the indicated times. (C) Colorectal (HT29,
Caco-2, LoVo, and SW480) and (D) non-colorectal (NCI-H292 lung, MCF7 breast, PC3 prostate, and
SqCC/Y1 head and neck) cancer cells were treated with vehicle or Resv (50 μM) for 24 h.
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Figure A.3. Resveratrol response element located within the -514 to +34 bp region of the ATF3
promoter. (A) Each indicated construct of the ATF3 promoter (0.5 μg) and pRL-null (0.05 μg) were
transiently transfected into HCT-116 cells and treated with vehicle or Resv (50 μM) for 24 h. The
promoter activity was measured as a ratio of firefly luciferase signal/renilla luciferase signal. The xaxis shows relative luciferase unit of each construct. The results are the mean SD of 3 replicates.
p < 0.05*; p < 0.01**; and p < 0.001***, on the basis of Student’s t test. (B) Nucleotide sequence
of the -514 to +34 bp region of the ATF3 promoter. Predicted binding sites of identified transcription
factors are capitalized and underlined with name located underneath.
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Figure A.4. Egr-1 and KLF4 contribute to resveratrol-induced ATF3 expression. Empty vector
(pcDNA3.1/NEO, EV) or the indicated expression vector (0.25 μg each) was co-transfected with
pATF3-514/+34 (A), pATF3-132/+34 (B), or pATF3-84/+34 (C) and pRL-null vector (0.05 μg) into
HCT-116 cells. Cells were then treated with vehicle or Resv (50 μM) in serum-free media for 24 h.
The x-axis shows fold induction relative to EV control. Data analyzed using Tukey’s multiple
comparison tests. Means with same letters indicate no significance (p < 0.05).
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Figure A.5. Both Egr-1 and KLF4 are involved in resveratrol induction of ATF3. (A) pATF3514/+34 or its internal deletion clones (0.5 μg) were transfected into HCT-116 cells followed by
treatment with vehicle or Resv (50 μM) in serum-free media for 24 h. Values were normalized to
vehicle treatment. The x-axis represents fold induction relative to the pATF3-514/+34 control. Data
analyzed using Tukey’s multiple comparison test; mean values with the same letters indicate no
significance (p < 0.05). (B) HCT-116 cells were transfected with Egr-1 sense/antisense
oligonucleotides or control/KLF4 siRNA using TransIT-TKO transfection reagent. Cells were serum
starved overnight and treated with vehicle or Resv (50 μM) for 6 h (KLF4) or 24 h (Egr-1). Protein
lysates were harvested and subjected to Western blot analysis for Egr-1 or KLF4, ATF3, and Actin.

103

Figure A.6. Egr-1 and KLF4 bind to the ATF3 promoter, EMSA. Gel shift assays were
performed using nuclear extracts (NE) from Resv (50 μM)-treated HCT-116 cells for 24 h or in vitro
translated (IVT) proteins as described in Chapter 2. Competitions were done in the presence of 10X
and 100X excess of unlabeled oligonucleotides (lanes 3-4 and 10-11). Specificity of the DNA/protein
complex was confirmed by the absence of competition with an excess of unlabeled mutated
oligonucleotide (lanes 5-6 and 12-13). A, Egr-1 and B, KLF4. Arrows, DNA/protein complexes.
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Figure A.7. Egr-1 and KLF4 bind to the ATF3 promoter, ChIP. HCT-116 cells were treated with
vehicle or Resv (50 μM) for 24 h. The chromatin/protein complexes were cross-linked by
formaldehyde treatment, and chromatin pellets were extracted and sonicated. The associated Egr-1
and KLF4 DNA was isolated as described in Chapter 2. The sequence of the human ATF3 promoter
(-298/-114) was amplified by PCR primer pairs (arrows). The input represents PCR products
obtained from 1% aliquots of chromatin pellets before immunoprecipitation. Left, ChIP qRT-PCR.
The x-axis shows enrichment relative to input. The results are the mean SD of three independent
experiments. Right, RT-PCR; representative gel picture of three experiments is shown.
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Figure A.8. de novo protein synthesis of Egr-1 and KLF4 is necessary for resveratrol-mediated
ATF3 activation. (A) HCT-116 cells were pretreated with cycloheximide (CHX, 10 mg/mL) for 30
min in serum-free media followed by treatment with Resv (50 μM) for 24 h. Values are normalized
fold induction relative to GAPDH expression. The data are representative of three independent
experiments. (B) HCT-116 cells were treated with vehicle or Resv (50 μM) in serum-free media for
24 h. RT-PCR was performed using Egr-1, KLF4, and GADPH human primers; the latter served as a
loading control. Representative gel pictures (top) and gel densitometry (bottom) of three independent
experiments are shown. Values are expressed as fold induction relative to vehicle-treated cells
adjusted to GAPDH. p< 0.05* and p< 0.01**, based on Student’s t test. (C) HCT-116 cells were
serum starved overnight and treated with Resv (50 μM) for the indicated times. Protein lysates were
harvested and subjected to Western blot analysis using ATF3, Egr-1, KLF4, and Actin antibodies.
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Figure A.9. Egr-1 and KLF4 coordinate the expression of resveratrol-induced ATF3 expression.
The pATF3-514/+34 reporter construct (0.25 μg) was co-transfected with pcDNA3.1 (empty), Egr-1,
and KLF4 expression vectors as indicated in the presence of pRL-null vector (0.05 μg). Cells were
treated with vehicle or Resv (50 μM) in serum-free media for 24 h. The y-axis shows fold induction
relative to pcDNA3.1 control. The results are the mean SD of three replicates. Data analyzed using
Tukey’s multiple comparison test; mean values with the same letters indicate no significance (p <
0.05).
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Figure A.10. Increased Egr-1 and KLF4 interact after resveratrol treatment. Mammalian 2hyrid assay was performed as described in Chapter 2. (A) HCT-116 cells were co-transfected with
pM and pVP16 vectors or pM/Egr-1 and pVP16/KLF4 vectors (0.2 μg each) in the presence of
pG5luc vector (0.2 μg) and pRL-null vector (0.06 μg). Cells were treated with vehicle, Resv (50 μM),
or DIM (25 μM) for 24 h in serum-free media. Promoter activity was measured as a ratio of firefly
luciferase/renilla luciferase signal, and the results are expressed as the mean SD of three
independent experiments. The y-axis shows fold induction over control vectors. Data analyzed using
Tukey’s multiple comparison test; mean values with the same letters indicate no significance (p <
0.05). (B) Top, schematic diagram of Egr-1 protein structure and locations used to generate internal
deletions. Bottom, HCT-116 cells were transfected with pM/Egr-1 internal deletion constructs,
pVP16/KLF4 vector, and pG5luc vector. Cells were treated with vehicle or Resv (50 μM) in serumfree media for 24 h. Values are normalized to vehicle treatment. The y-axis represents fold induction
relative to pM/Egr-1 and pVP16/KLF4 control. Data analyzed using Tukey’s multiple comparison
test; mean values with the same letters indicate no significance (p < 0.05).
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Figure A.11. Confirmation of Egr-1 and KLF4 interaction in the presence of resveratrol. HCT116 cells were transfected with empty (EV), Egr-1 (WT or deletion), or co-transfected with KLF4
expression vectors as indicated and grown to 80% confluence. Cells were serum starved overnight,
treated with Resv (50 μM) for 2 h, and harvested as described in Chapter 2. Cell extracts were
immunoprecipitated and immunoblotted with antibody against Egr-1 or KLF4.
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Figure A.12. Relevance of ATF3 in resveratrol-induced apoptosis. Caspase 3/7 enzymatic
activity was measured as described in Chapter 2. (A) HCT-116 and HT29 cells were treated with 0,
10, 50, and 100 μM Resv for 24 h. Data analyzed using Tukey’s multiple comparison test; mean
values with the same letter indicate no significance (p < 0.05). (B) HCT-116 and HT29 cells were
transfected with empty or ATF3 expression vector and grown to 60% to 80% confluence. Cells were
serum starved overnight and treated with the pan caspase inhibitor z-vad-fmk (ZVF, 1 μM) for 3 h.
ATF3 overexpression was validated (top). (C) HCT-116 cells were transfected with control/ATF3
siRNA using TransIT-TKO transfection reagent and treated with Resv (50 μM) for 24 h. ATF3
knockdown was validated (left). p < 0.01** and p < 0.001***, on the basis of Student’s t test.
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Figure A.13. Egr-1 and KLF4 activate ATF3 independent of resveratrol. Empty vector or the
indicated expression vector (0.25 μg each) was co-transfected with the ATF3 promoter construct in
the presence of pRL-null vector (0.05 μg) into HCT-116 cells. Promoter activity was measured as a
ratio of firefly luciferase signal/renilla luciferase signal. The x-axis shows fold induction relative to
pcDNA3.1 control. The results are the means ± SD of three replicates. A, Egr-1 and B, KLF4.
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A.14. Posttranscriptional regulation of ATF3 as an alternate regulatory pathway. HCT-116
cells were incubated with vehicle or Resv (50 μM) for 24 h and subsequently treated with
antinomycin D (Act D, 5 μM). At the indicated times, total RNA was isolated, and RT-PCR was
performed using ATF3 and GAPDH human specific primers, the latter served as a loading control.
Representative gel pictures (top) and gel densitometry (bottom) of three independent experiments are
shown. Values are expressed as percentage of relative ATF3 transcript present at Time 0 of Act D
treatment.
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APPENDIX B:
Figures for Chapter 4
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Figure B.1. Resveratrol decreases serine 27 SIRT1 phosphorylation. HCT-116 cells were seeded
and grown to 60% to 80% confluence, serum starved overnight, and treated with Resv as indicated in
serum-free media. Protein lysates were harvested and subjected to Western blot analysis using
pSIRT1 (Ser 27), pSIRT1 (Ser 47), SIRT1, and Actin antibodies.
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Figure B.2. Increased Egr-1 activity by resveratrol is SIRT1-independent. (A) HCT-116 cells
were co-transfected with EV and pEBS14luc vectors (0.25 μg each) or Egr-1 and pEBS14luc vectors
(0.25 g each) in the presence of SIRT1 expression vector (0.25 μg) and pRL-null vector (0.0075 μg).
Cells were treated with vehicle or Resv (50 μM) for 24 h in serum-free media. (B) pBABE or SIRT1
(0.375 μg) was co-transfected with pEgr-1 -1260/+35 (0.375 μg) or pRL-null vector (0.0075 μg) into
HCT-116 cells and treated with vehicle or Resv (50 μM) in serum-free media for 24 h. Promoter
activity for (A) and (B) was measured as a ratio of firefly luciferase signal/renilla luciferase signal,
and the results are expressed as the mean ± SD of 3 replicates. The y-axis shows fold induction over
vehicle control.
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Figure B.3. Egr-1 amino acid sequence and predicted acetylation site.

Figure B.4. Egr-1 aDaa mutation diminishes resveratrol-induced Egr-1 activity. (A) HCT-116
cells were transfected with EV, Egr-1 WT, or Egr-1 aDaa vectors and grown to 80% confluence.
Cells were serum starved overnight, treated with Resv (50 μM) for 2 h, and harvested as described in
Chapter 2. The cell extracts were immunoprecipiated with Egr-1 and immunoblotted with antibody
against Egr-1 and acetylated lysine. (B) EV, Egr-1, or Egr-1 aDaa expression vector (0.375 μg each)
was co-transfected with pEBS14luc (0.375 μg) and pRL-null vector (0.0075 μg) into HCT-116 cells.
Cells were then treated with vehicle or Resv (50 μM) in serum-free media for 24 h. The promoter
activity was measured as a ratio of firefly luciferase signal/renilla luciferase signal. The y-axis shows
fold change relative to vehicle control. The results are the mean ± SD of 3 replicates. Data analyzed
using Tukey’s multiple comparison test; mean values with same letters indicate no significance (P <
0.05).
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Figure B.5. Acetylation contributes to activation of the Egr-1 target gene, NAG-1. HCT-116
cells were transfected with EV, Egr-1 WT, or Egr-1 aDaa and grown to 80% confluence. (A) Cells
were serum starved overnight and pre-treated with Resv (50 μM) for 2 h followed by TSA (1 μM) for
24 h as indicated. Protein lysates were harvested and subjected to Western blot analysis using ATF3,
NAG-1, p53, Egr-1, and Actin antibodies. (B) qRT-PCR was performed as described in Chapter 2
for NAG-1. Values are normalized to fold induction relative to GAPDH expression. The data are
representative of 3 independent experiments.

117

Figure B.6. Acetylation contributes to NAG-1 promoter binding and transactivation by Egr-1.
HCT-116 cells were transfected with EV, Egr-1 WT, or Egr-1 aDaa vectors and grown to 80%
confluence. (A) The sequence of the human NAG-1 promoter (-133/+31) was amplified by PCR
primer pairs. The input represents PCR products obtained from 1% aliquots of chromatin pellets
before immunoprecipitation. Representative gel picture of three experiments is shown. (B) Each
vector (0.375 μg) was co-transfected with pNAG-1 -133/+41 (0.375 μg) or pRL-null vector (0.0075
μg) into HCT-116 cells and treated with vehicle or Resv (50 μM) in serum-free media for 24 h.
Promoter activity for was measured as a ratio of firefly luciferase signal/renilla luciferase signal, and
the results are expressed as the mean ± SD of 3 replicates. The y-axis shows fold induction over
vehicle control. p < 0.001***, on the basis of Student’s t test.
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